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SEX DIFFERENCES IN MORPHINE ANALGESIA AND THE DESCENDING
MODULATION OF PAIN

by

DAYNA R. LOYD

Under the Direction of Anne Z. Murphy, Ph.D.

ABSTRACT
Morphine is the most widely prescribed opiate for alleviation of persistent pain; however,
it is becoming increasingly clear that morphine is less potent in women compared to
men. Morphine primarily binds mu opioid receptors, which are densely localized in the
midbrain periaqueductal gray (PAG). Anatomical and physiological studies conducted in
the 1960s identified the PAG, and its projections to the rostral ventromedial medulla
(RVM) and spinal cord dorsal horn, as an essential neural circuit mediating opioidbased analgesia. Remarkably, the majority of studies since then were conducted in
males with the implicit assumption that this circuit was the same in females; this is not
the case. It is now well established that morphine produces greater analgesia in males
compared to females in a wide range of vertebrates, however, the mechanism(s) driving
this sex difference is not clear. Our recent studies indicate that two factors appear to be
contributing to the sexually dimorphic effects of morphine. First, there are sex

differences in the anatomy and physiology of the descending inhibitory pathway on
which morphine acts to produce analgesia. Specifically, the projections from the PAG to
the RVM are sexually dimorphic and activated to a greater degree by both inflammatory
pain and systemic morphine in males. In the absence of pain, the PAG-RVM circuit is
activated to a greater degree in males compared to females, while this activation
steadily declines during the development of tolerance in males only. We also have
evidence of a sexually dimorphic expression of mu opioid receptor within the PAG that
appears to contribute to sex differences in morphine potency. Microinjection of
morphine directly into the PAG produces significantly greater analgesia in males,
indicating that the PAG is sufficient for eliciting this sexually dimorphic behavior.
Furthermore, mu opioid receptor-expressing PAG neurons are necessary for eliciting a
sexually dimorphic response to morphine as lesioning mu opioid receptor-expressing
neurons attenuates analgesia in males only. Together, these data indicate that the
PAG-RVM pathway and mu opioid receptor expression in the PAG is sexually dimorphic
and provides a primary mechanism for sex differences in morphine potency.

INDEX WORDS: periaqueductal gray, rostral ventromedial medulla, endogenous
descending pathway, antinociception, nociception, inflammation, antihyperalgesia
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CHAPTER ONE

INTRODUCTORY OVERVIEW

Submitted for Publication as a Review in Neural Plasticity: A Special Issue on the PAG
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1.1 HISTORY OF A DESCENDING PAIN MODULATORY PATHWAY IN MALES
In 1969, a novel field of research emerged when it was first reported that electrical
stimulation of a midbrain structure, the periaqueductal gray (PAG), produced profound
analgesia in the male rat (Reynolds, 1969). Remarkably, the stimulation-elicited
analgesia from the PAG was sufficient to allow for invasive abdominal surgical
procedures to be performed (Mayer et al., 1971). Further research soon revealed that
stimulation-elicited analgesia from the lateral and ventrolateral PAG produced “pure
analgesia” with no other behavioral alterations (Guilbaud et al., 1972; Liebeskind et al.,
1973; Oliveras et al., 1974), while stimulation of loci mainly within the dorsal and lateral
PAG also produced increased motor behavior (Jacquet & Lajtha, 1973; 1974) and
vocalization (Fardin et al., 1984b; a). These findings launched an extensive effort to
characterize the neural mechanisms driving this descending control of pain. In 1976,
Akil et al. reported that administration of the opioid receptor antagonist naloxone
partially attenuated PAG stimulation-produced analgesia (Akil et al., 1976), implicating
the endogenous opioid system. Later, it was reported that administration of opioid
receptor agonists into the PAG produced potent analgesia that was blocked by either
central or systemic administration of naloxone (Satoh et al., 1983; Jensen & Yaksh,
1986; Bodnar et al., 1988b).
During the search for the descending neural pathways involved in analgesia, stimulation
of both the PAG and a novel area, the nucleus raphe magnus of the rostral
ventromedial medulla (RVM), were reported to preferentially inhibit nociceptive dorsal
horn neurons thus producing antinociception (Liebeskind et al., 1973; Fields et al.,
1977; Carstens et al., 1979; Jensen & Yaksh, 1984; Sandkuhler & Gebhart, 1984; Light
2

et al., 1986; Sandkuhler et al., 1988; Zhang et al., 1991), an effect that was reversible
with naloxone treatment in both rats (Jones & Gebhart, 1988) and humans (Hosobuchi
et al., 1977). At the time, it was unknown how the PAG and the RVM provided inhibitory
input to the nociceptive dorsal horn neurons. Even though the PAG had been shown to
produce profound antinociception, there was little evidence of a direct projection from
the PAG to the spinal cord dorsal horn (Mantyh & Peschanski, 1982). Alternatively, the
pioneering studies of Basbaum and Fields (1979) demonstrated that the descending
projections in the dorsolateral funiculus, a major spinal cord nerve fiber tract, were
involved in PAG-mediated antinociception. In addition, the majority of axons that travel
through the dorsolateral funiculus were reported to arise from the RVM (Basbaum &
Fields, 1979; Abols & Basbaum, 1981; Lakos & Basbaum, 1988; Sim & Joseph, 1992).
Indeed, lesions of the RVM or dorsolateral funiculus were found to abolish or
significantly attenuate PAG-produced antinociception (Proudfit & Anderson, 1975;
Basbaum et al., 1977; Chance et al., 1978; Mohrland & Gebhart, 1980; Proudfit, 1980;
Gebhart et al., 1983; Prieto et al., 1983; Sandkuhler & Gebhart, 1984; Guo & Tang,
1990). Later, electrophysiological studies reported an excitatory projection from the
PAG to spinally projecting neurons in the RVM (Basbaum & Fields, 1979; Behbehani &
Fields, 1979; Shah & Dostrovsky, 1980; Behbehani, 1981; Behbehani et al., 1981;
Behbehani, 1982) and this projection was further characterized by multiple tract-tracing
studies (Beitz et al., 1983; Lakos & Basbaum, 1988; Li et al., 1990).
The anatomical and physiological organization of the PAG (Beitz, 1985; Beitz &
Shepard, 1985) and, in particular, the PAG-RVM-spinal cord circuit is now well
characterized in a variety of species, including the rat (Basbaum & Fields, 1978;
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Behbehani & Fields, 1979; Beitz, 1982b; Beitz et al., 1983; Beitz, 1985; Beitz &
Shepard, 1985; Jones & Light, 1992; Williams et al., 1995), cat (Basbaum et al., 1978;
Shah & Dostrovsky, 1980; Abols & Basbaum, 1981; Sandkuhler et al., 1987a;
Sandkuhler et al., 1987b; Holstege & Cowie, 1989; Vanderhorst et al., 1996;
VanderHorst et al., 1998; Mouton & Holstege, 2000), squirrel monkey (Mantyh, 1983;
Gerhart et al., 1984), and rabbit (Haselton et al., 1988) (see Figure 2.1). Subsequent
anatomical studies characterized the efferents and afferents of the PAG (Beitz, 1982a;
c) and further demonstrated the central role of the PAG in both stimulation-produced
and opioid-induced antinociception (Basbaum et al., 1976; Basbaum et al., 1977; Barton
et al., 1980; Morgan et al., 1992). It is now clear that the PAG, and its descending
projections to the RVM and spinal cord, comprises an essential neural circuit for both
endogenous and exogenous opioid-mediated antinociception (Basbaum et al., 1978;
Basbaum & Fields, 1978; Basbaum & Fields, 1984).
An extensive amount of research has focused on the mechanisms whereby opiates, the
exogenous analgesics, produce antinociception via the PAG. Involvement of opiates in
PAG-mediated antinociception was first demonstrated in 1978, when microinjection of
the mu opioid receptor agonist morphine into the PAG produced naloxone-reversible
antinociception (Yaksh & Rudy, 1978), and specifically, naloxone-reversible excitation of
RVM neurons (Behbehani & Fields, 1979; Cheng et al., 1986; Morgan et al., 1992).
Studies utilizing both autoradiography and immunohistochemistry reported that the PAG
contained a high density of mu opioid receptors (Mansour et al., 1986; Mansour et al.,
1987; Kalyuzhny et al., 1996; Gutstein et al., 1998; Commons et al., 1999; Commons et
al., 2000b; Wang & Wessendorf, 2002). Antinociception produced by opioid
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microinjection into the PAG has now been repeated and confirmed in a variety of
species (Pert & Yaksh, 1974; Jacquet & Lajtha, 1976; Mohrland & Gebhart, 1980;
Kayser & Guilbaud, 1983; Gebhart et al., 1984; Ossipov et al., 1984; Camarata &
Yaksh, 1985; Jensen & Yaksh, 1986; Carstens et al., 1988; Carstens et al., 1990).
Similarly, lesions of the PAG or microinjection of mu opioid receptor antagonists into the
PAG (Wilcox et al., 1979; Ma & Han, 1991; Zhang et al., 1998) attenuate the
antinociceptive effects of systemic morphine across a wide range of analgesiometric
tests (Lewis & Gebhart, 1977).
By the 1990’s, electrophysiological studies reported that morphine, as well as other
opioid agonists, inhibit and excite different populations of PAG neurons, including PAG
neurons projecting to the RVM (PAG-RVM neurons). Indeed, two mechanisms for
morphine’s antinociceptive actions at the level of the PAG have been proposed: (1)
opioids disinhibit PAG-RVM neurons by presynaptically inhibiting tonically active
GABAergic neurons (Behbehani et al., 1990a; Behbehani et al., 1990b; Chieng &
Christie, 1994a; Stiller et al., 1995), thus resulting in the activation of PAG-RVM
neurons; and (2) opiates directly inhibit a subset of PAG-RVM neurons localized
primarily in the lateral and ventrolateral PAG (Chieng & Christie, 1994a; Osborne et al.,
1996b). Soon it was reported that mu opioid receptors were localized on approximately
27-50% of PAG neurons retrogradely labeled from the RVM (Commons et al., 2000b;
Wang & Wessendorf, 2002).

5

1.2 BUT WHAT ABOUT FEMALES? SEX DIFFERENCES IN MORPHINE
ANALGESIA
While it is well established that the PAG-RVM-spinal cord pathway is essential for the
analgesic actions of both systemic and intra-PAG morphine, these early studies were
conducted exclusively in male subjects. Only recently have studies begun including
‘sex’ as an independent variable, and it is becoming increasingly clear that morphine
does not produce the same degree of antinociception in males and females, especially
following the induction of persistent pain. Sex differences in morphine potency were first
reported in rodents in the late 1980’s, when it was shown that morphine produced a
significantly greater degree of antinociception in males compared to females in studies
employing acute pain assays (Kavaliers & Innes, 1987; Baamonde et al., 1989; Kepler
et al., 1989; Kepler et al., 1991). Indeed, the vast majority of studies to date confirm this
effect, including studies employing orofacial (Okamoto et al., 2005) and visceral (Ji et
al., 2006; 2007) pain models, as well as persistent somatic pain models (Bartok & Craft,
1997; Cicero et al., 1997; Boyer et al., 1998; Kest et al., 1999; Barrett et al., 2001; Cook
& Nickerson, 2005; Wang et al., 2006). Sex differences in the antihyperalgesic effects of
morphine are not trivial; in both persistent inflammatory pain (Wang et al., 2006) and
visceral pain (Ji et al., 2006; 2007) studies, the ED50 for females was twice the ED50 of
males. This is quite a remarkable difference, and to date, the mechanism(s) underlying
the sexually dimorphic actions of morphine remain unknown.
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1.3 ROLE OF GONADAL HORMONES IN SEX DIFFERENCES IN MORPHINE
ANALGESIA
Sex differences in gonadal hormone concentrations contribute to sex differences in
morphine analgesia (Kepler et al., 1989; Islam et al., 1993; Krzanowska & Bodnar,
1999; 2000; Stoffel et al., 2003; Cataldo et al., 2005; Stoffel et al., 2005). In females, the
primary gonadal hormones are estradiol and progesterone, while in males it is
testosterone. Both centrally and peripherally, testosterone is aromatized to estradiol,
thus male and females both secrete steroid hormones that bind both androgen
receptors (AR) and estrogen receptors (ERα and ERβ).
Numerous behavioral studies have suggested that both the organizational and
activational actions of gonadal steroids can have an effect on morphine analgesia
(Kepler et al., 1989; Islam et al., 1993; Krzanowska & Bodnar, 1999; 2000; Stoffel et al.,
2003; Cataldo et al., 2005; Stoffel et al., 2005). Compared to normal controls, male rats
castrated at birth demonstrate reduced morphine potency in adulthood, while female
rats masculinized at birth demonstrate greater morphine potency in adulthood (Cicero et
al., 2002; Krzanowska et al., 2002). Similarly, morphine is less effective in
gonadectomized adult males and more effective in ovariectomized adult females
(Kepler et al., 1989; Ratka & Simpkins, 1991; Krzanowska & Bodnar, 1999; Terner et
al., 2002; Stoffel et al., 2003; Stoffel et al., 2005; Terner et al., 2005). These effects can
be reversed with hormone replacement treatment (Ratka & Simpkins, 1991; Kiefel &
Bodnar, 1992; Ji et al., 2007). In females, circulating levels of estradiol across the
estrous cycle reportedly influence morphine antinociception, with greater potency
reported during diestrus, when circulating estradiol is lowest (Stoffel et al., 2003; Craft et
7

al., 2004; Okamoto et al., 2005; Stoffel et al., 2005; Terner et al., 2005). In fact,
microinjection of morphine directly into the PAG produces significantly lower
antinociception during the estrus stage in female rats, while there was no significant
difference in morphine potency between females in diestrus compared to males (Bernal
et al., 2007).

1.4 CLINICAL EVIDENCE OF SEX DIFFERENCES IN MORPHINE ANALGESIA
Recently, clinical studies in humans have also reported sex differences in morphine
analgesia. Of the limited number of studies that examined sex (gender) as an
independent variable, the majority reported that males experience greater analgesia
compared to females (Cepeda et al., 2002; Cepeda & Carr, 2003; Miller & Ernst, 2004).
In fact, one study reported that females required 30% more morphine to reach the same
level of analgesia as males (Cepeda & Carr, 2003). Results to the contrary have also
been reported; Sarton et al. reported greater morphine antinociception in females
(Sarton et al., 2000), while two studies reported no sex difference (Gordon et al., 1995;
Fillingim et al., 2005). Sex differences in morphine consumption have also been
reported (Miaskowski et al., 2000); however, morphine consumption is not a reliable
indicator of morphine analgesia, particularly given that all of the negative side effects
associated with morphine consumption, including nausea, headache and dysphoria, are
exacerbated in females compared to males (Cepeda et al., 2003; Fillingim et al., 2005).
Importantly, sex differences in morphine analgesia are not due to sex differences in the
pharmacokinetics of morphine [humans (Sarton et al., 2000) or rodents (Cicero et al.,
1997)]. Rather, sex differences in morphine analgesia are likely due to the inherent
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differences in how the central nervous system of males and females responds to
exogenous opioids.

1.5 DISSERTATION AIMS
Given that the PAG and its descending projections to the RVM and dorsal horn of the
spinal cord provide a primary pathway for the actions of exogenous opiates on pain
modulation, we hypothesized that (1) sex differences in the anatomy and physiology of
the PAG-RVM pathway are responsible for differential morphine potency in a rat model
of inflammatory pain; and (2) a sexually dimorphic expression of mu opioid receptor is a
necessary and sufficient mechanism within the PAG for eliciting sexually dimorphic
morphine analgesia. The dissertation research reported here tested these hypotheses
via the following questions: (1) Are there sex differences in the anatomical organization
of the PAG-RVM pathway? (2) Is there a sexually dimorphic response of the PAG-RVM
output neurons to persistent pain? (3) Does administration of morphine, both during
inflammatory pain and in the absence of pain, differentially engage the PAG-RVM
pathway in male and female rats? and (4) Are mu opioid receptor-expressing neurons in
the PAG necessary and sufficient in eliciting sex differences in morphine analgesia?
The objective of this research is to provide evidence of a primary mechanism
responsible for driving observed sex differences in morphine potency. It is intended that
the findings of this research will ultimately improve the treatment of persistent pain in
the clinical setting.

9

Figure 1.1. A schematic of the descending inhibitory pathway for pain modulation
illustrating the projections from the midbrain periaqueductal gray to the brainstem rostral
ventromedial medulla and the spinal cord dorsal horn.
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CHAPTER TWO

Sex Differences in the Anatomical and Functional Organization of the
Periaqueductal Gray - Rostral Ventromedial Medullary Pathway in the
Rat: A Potential Circuit Mediating the Sexually Dimorphic Actions of
Morphine
Dayna R. Loyd and Anne Z. Murphy
Department of Biology, Center for Behavioral Neuroscience
Georgia State University, Atlanta, Georgia 30302-4010

Published in the Journal of Comparative Neurology (2006) 496: 723-738
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2.1 ABSTRACT
Previous studies have demonstrated that morphine, administered systemically or
directly into the PAG, produces a significantly greater degree of antinociception in males
in comparison to females. As the midbrain periaqueductal gray (PAG) and its
descending projections to the rostral ventromedial medulla (RVM) constitute an
essential neural circuit for opioid-based analgesia, the present studies were conducted
to determine if sex differences in the anatomical organization of the PAG-RVM pathway,
and its activation during persistent inflammatory pain, could account for sex-based
differences in opioid analgesia. In the rat, retrograde tracing was combined with Fos
immunocytochemistry to investigate sexual dimorphism in the organization of the PAGRVM circuit and its activation by persistent inflammatory pain induced by intraplantar
injection of complete Freund’s adjuvant (CFA). The ability of morphine to suppress the
activation of the PAG-RVM circuit was also examined. Sexually dimorphic retrograde
labeling was observed within the dorsomedial and lateral/ventrolateral PAG at all
rostrocaudal levels, with females having significantly more PAG-RVM output neurons in
comparison to males. While no sex differences were noted in the activation of the PAGRVM circuit by persistent inflammatory pain, significantly more double labeled cells
were found in males in comparison to females. Systemic administration of morphine
significantly suppressed CFA-induced Fos in the PAG in males only. The results of
these studies demonstrate that both the anatomical organization, and functional
activation, of the PAG-RVM circuit is sexually dimorphic, and may provide the
anatomical substrate for sex-based differences in morphine analgesia.
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2.2 INTRODUCTION
It is becoming increasingly clear that morphine produces a differential degree of
analgesia in males and females. In studies using either acute (Kepler et al., 1989; Islam
et al., 1993; Cicero et al., 1996a; 1997) or persistent pain models (Cook & Nickerson,
2005; Wang & Murphy, 2005), morphine has been shown to produce a significantly
greater degree of analgesia in males in comparison to females. Similar findings have
also been reported in humans (Cepeda & Carr, 2003; Miller & Ernst, 2004). The
midbrain periaqueductal gray (PAG), along with its descending projections to the rostral
ventromedial medulla (RVM), is one of the primary anatomical substrates mediating
opioid analgesia. Administration of mu opioid receptor agonists into the PAG produces
potent analgesia that is blocked by central or systemic administration of the opioid
antagonist naloxone (Satoh et al., 1983; Jensen & Yaksh, 1986; Bodnar et al., 1988b).
Similarly, lesions of the PAG or intra-PAG administration of mu opioid receptor (MOR)
antagonists (Wilcox et al., 1979; Ma & Han, 1991; Zhang et al., 1998) attenuate the
antinociceptive effects of systemic morphine. Together, these studies indicate that the
PAG is an essential locus for opioid-mediated analgesia.
There are no direct projections from the PAG to the dorsal horn of the spinal cord.
Rather, the PAG projects heavily onto reticulospinal neurons of the RVM (Beitz, 1982b;
Beitz et al., 1983; van Bockstaele et al., 1991; Cameron et al., 1995b), and this PAGRVM-spinal cord circuit is essential for the analgesic actions of systemic or intra-PAG
morphine. Lesions of the RVM or dorsolateral funiculus (DLF) completely abolish PAG
opiate-produced analgesia (Proudfit & Anderson, 1975; Basbaum et al., 1977; Chance
et al., 1978; Mohrland & Gebhart, 1980; Proudfit, 1980; Guo & Tang, 1990). In fact,
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lesions of the DLF attenuate all analgesic manipulations tested, including systemic,
intraventricular and intrathecally administered morphine, indicating that the PAG-RVMspinal cord pathway is the critical neural circuit for opioid-induced analgesia.
The anatomical and physiological organization of the PAG-RVM-spinal cord circuit has
been well characterized in a variety of species, including the rat (Basbaum & Fields,
1978; Behbehani & Fields, 1979; Beitz, 1982b; Jones & Light, 1992; Williams et al.,
1995), cat (Basbaum et al., 1978; Shah & Dostrovsky, 1980; Abols & Basbaum, 1981;
Sandkuhler et al., 1987a; Sandkuhler et al., 1987b; Holstege & Cowie, 1989), squirrel
monkey (Mantyh, 1983; Gerhart et al., 1984), and rabbit (Haselton et al., 1988).
However to date, all of these studies have been conducted exclusively in male animals.
Therefore, it is not known if the PAG-RVM-spinal cord circuit is organized anatomically
in a similar manner in females. Sex differences in the organization of this circuit may
provide an anatomical substrate for the observed sex differences in opioid analgesia.
The present studies were conducted to determine if the PAG-RVM circuit is organized
differentially in males and females. Additional behavioral studies were performed to
examine the activation of this circuit by persistent inflammatory pain. The results of
these studies demonstrate for the first time that the PAG-RVM circuit is sexually
dimorphic in both its anatomical organization and in its functional activation during
persistent inflammatory pain. Collectively, these data suggest that the PAG, and its
descending projections to the RVM, may provide the anatomical substrate for the
observed sex differences in morphine analgesia. Portions of this paper have been
previously published in abstract form (Loyd & Murphy, 2004b).
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2.3 METHODS
Subjects
Fifteen adult intact male Sprague-Dawley rats and fifteen adult cycling female SpragueDawley rats (Zivic-Miller) were used in these experiments. Animals were weightmatched (250-300g) and housed in same-sex pairs in separate rooms on a 12:12 hour
light: dark cycle (lights on at 7:00A.M.). Access to food and water was available ad
libitum throughout the experiment except during surgery. These studies were
performed in strict compliance with the Institutional Animal Care and Use Committee at
Georgia State University. All efforts were made to minimize any possible suffering by
the animal, and to reduce the number of animals used.
Iontophoresis Injections
Twelve male and twelve female rats were anesthetized with ketamine/xylazine (50
mg/kg/10mg/kg; s.c.) and placed in a stereotaxic frame upon achieving a deep surgical
plane of anesthesia. The skull was adjusted so that bregma and lambda were at the
same dorsoventral coordinate. Glass micropipettes (10-20 µM) were filled with the
retrograde tracer Fluorogold (FG; 2% soln. w/v in saline; Fluorochrome Inc.) and
lowered into the RVM at the following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0;
DV: -8.5. FG was iontophoresed (50/50 duty cycle, 7.5 µA current) for 20 min. Pipettes
remained in place for five minutes after injection to prevent backflow of tracer along the
pipette tract and to facilitate neuronal uptake. Special care was taken to ensure that all
injection protocols were comparable for males and females. Following surgery the
animals were allowed to recover under a heat lamp in clean cages, and returned to their
original housing facilities upon recovery from the anesthetic.
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Inflammatory Hyperalgesia
Ten days following surgery, persistent inflammatory pain was induced by injection of
complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl),
suspended in an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw.
Animals were under brief Isoflo (isofluorane, USP) anesthesia during the plantar
injections. We have previously used this procedure to induce persistent inflammatory
pain and reported no sex differences in the degree of edema produced by intraplantar
CFA, nor in the ensuing hyperalgesia, assayed using the paw thermal stimulator (Wang
and Murphy, 2005).
Morphine Analgesia
Twenty-four hours following the induction of inflammation, all FG-injected animals were
given a subcutaneous injection of either morphine sulfate (4.5mg/kg, s.c.; NIDA) or the
drug vehicle as a control. Morphine sulfate was prepared fresh in a saline vehicle on the
day of the experiment.
Perfusion fixation
One hour after morphine administration, animals were given a euthanizing dose of
Nembutal (160mg/kg; i.p.). Upon achieving a deep surgical plane, the animals were
perfused transcardially (descending aorta clamped) with 100-200 ml of 0.9% sodium
chloride containing 2% sodium nitrite as a vasodilator, followed immediately by 250 ml
of 4% paraformaldehyde in 0.1M phosphate buffer containing 2.5% acrolein
(Polyscience). Following fixation, a final rinse with the sodium chloride/sodium nitrate
solution was used to remove any residual acrolein from the animal. Immediately
following perfusion, the brains were removed and a mark made along the base of the
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brain to demarcate left from right side. The tissue was stored at 4oC in 30% sucrose
solution until sectioned. The dura and pia mater were removed and the brains were cut
into 25µm coronal sections with a Leica 2000R freezing microtome and stored freefloating in cryoprotectant-antifreeze solution (Watson et al., 1986a) at –20oC until
immunocytochemical processing was initiated.
Immunocytochemistry
A 1:6 series through the rostrocaudal axis of each brain was processed for FG and/or
Fos immunoreactivity as previously described (Murphy & Hoffman, 2001). Briefly,
sections were removed from the cryoprotectant-antifreeze solution, rinsed extensively in
potassium phosphate-buffered saline, and then reacted for 20 minutes in 1% sodium
borohydride to remove excess aldehydes. Sections were then incubated in primary
antibody solution directed against either Fos or FG in KPBS containing 0.1% Triton X
for 1 hour at room temperature followed by 48 hours at 4°C. Cells containing Fos were
identified using the polyclonal rabbit anti-Fos antibody (Oncogene, Cat. No. PC38; lot
no. 4194) at a concentration of 1:50,000. This rabbit antiserum was prepared against
the synthetic peptide (SGFNADYEASSSRC) corresponding to amino acids 4-17 of
human c-Fos. In western blots, this antibody recognizes the ~55 kDa c-Fos and ~62
kDa v-Fos proteins, and does not cross-react with the ~39 kDa Jun protein
(manufacturer’s technical information). FG containing cells were recognized using the
polyclonal rabbit anti-Fluorogold antibody (Chemicon, Cat. No. AB153; lot no.
25060005) at a concentration of 1:10,000. This antibody was raised against the
chemical compound hydroxystildamidine. No cytoplasmic FG staining was present in
animals in which the tracer failed to be ejected from the electrode. In addition, the

17

retrograde labeling pattern in the PAG noted with this antibody is identical to published
reports using alternative retrograde tracers (Rizvi et al., 1996; Beitz et al., 1983).
After rinsing in KPBS, the tissue was incubated for 1 hour in biotinylated goat anti-rabbit
IgG (Jackson Immunoresearch, 1:200), rinsed in KPBS, followed by a 1 hour incubation
in avidin-biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in
KPBS and sodium acetate (0.175 M; pH 6.5), Fos was always visualized as a black
reaction product using nickel sulfate intensified 3,3’-diaminobenzidine solution
containing 0.08% hydrogen peroxide in sodium acetate buffer. FG was always
visualized as a brown reaction product using 3,3’-diaminobenzidine containing 0.08%
hydrogen peroxide in Tris buffer (pH 7.2). The reaction product was terminated after 725 minutes by rinsing in sodium acetate buffer.
For dual labeling, sections were first processed for Fos immunocytochemistry as
described above. Following visualization of Fos, sections were rinsed several times in
KPBS and then incubated for 1 hour at room temperature in primary antibody directed
against FG followed by 48 hours at 4°C. Secondary and ABC reactions are as stated
above. FG was visualized as a brown reaction product using 3,3’-diaminobenzidine
containing 0.08% hydrogen peroxide in Tris buffer (pH 7.2) for a brown cytoplasmic
reaction product. Sections were mounted out of saline onto gelatin-subbed slides, airdried overnight, dehydrated in a series of graded alcohols, cleared in Histoclear, and
cover-slipped using Histomount.
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Data Analysis and Presentation
Previous anatomical studies have demonstrated that the PAG is not a homogenous
structure, but rather has distinct afferents, efferents and neurochemical composition that
are dependent on the rostrocaudal level (van Bockstaele et al., 1991; Bandler &
Shipley, 1994a). Therefore, the number of FG+, Fos+, or Fos+FG neurons was
determined for six rostrocaudal levels of PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, 8.80). Fos counts were made ipsilateral to the CFA-injected paw. In our preliminary
studies (Loyd and Murphy, 2004), no differences were noted in the number of FG+ cells
for the left versus right side of PAG; similarly, no laterality was observed in CFA-induced
Fos expression in the PAG. Therefore, FG, Fos and Fos+FG labeled cells were only
counted for the side ipsilateral to the CFA injected paw.
Results for each rostrocaudal level of the PAG are expressed as the mean + standard
error of the mean (SEM). Only animals with comparable injection sites limited to the
RVM were used for analysis. Neurons were counted in two PAG subdivisions:
dorsomedial and lateral/ventrolateral; these subdivisions are clearly distinguishable
based on the distribution of retrograde labeling from the RVM (van Bockstaele et al.,
1991; Bandler & Shipley, 1994a). Sections (25 µm thick) were immunocytochemically
processed in a 1:6 series; therefore, each section analyzed is separated by 125µm. Cell
counts were adjusted (Guillery, 2002) taking into consideration that PAG somal sizes
range between 11-40µm (Lovick & Stezhka, 1999), with a mean somal length of 14.8µm
(Beitz, 1985; Beitz & Shepard, 1985).
Analysis of variance (ANOVA) was used to test for significant main effects of sex (male,
female), PAG subdivision (dorsomedial, lateral/ventrolateral), PAG level (Bregma –6.72
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through -8.80); treatment (morphine, saline) was included as a fourth factor where
relevant. P<0.05 was considered significant for all analyses. To determine the PAG
area, an image of the section was captured with a 4x objective on a Nikon Eclipse E800
microscope using a Sensys digital camera (Biovisions Technology, Exton, PA). With IP
Spectrum software (Scanalytics, Fairfax, VA), the PAG area (in mm2) was determined.
For data presentation, a representative animal from each experimental group was
selected and the distribution of FG and Fos within the PAG were plotted using a Nikon
Drawing Tube attached to a Nikon Optiphot microscope. Plots were imported to the
computer and finalized using Adobe Illustrator 10. Photomicrographs were generated
using a Synsys digital camera attached to a Nikon Eclipse E800 microscope. Images
were captured with IP Spectrum software and finalized using Adobe Photoshop 7.0.
Alterations to the images were strictly limited to enhancement of brightness/contrast.

2.4 RESULTS
Sexually Dimorphic Anatomical Organization of the PAG-RVM Circuit
Figure 2.1 shows an example of a typical iontophoretic injection of the retrograde tracer
Fluorogold (FG) into the RVM of a male (top; n=12) and female (bottom; n=12) rat. All
injections were located on the midline and dorsal to the pyramidal tract, just caudal to
the level of the facial nucleus (Lambda –2.0). Injections outside of the RVM were not
included for analysis. Injection of FG into the RVM produced dense retrograde labeling
throughout the rostral-caudal axis of the PAG in both males and females (Figure 2.2).
Within the rostral half of PAG (Bregma –6.72 - –7.64), retrogradely labeled cells were
concentrated within the dorsomedial and lateral regions of PAG. A few scattered cells
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were present within the ventrolateral PAG. More caudally (Bregma –8.0 - –8.30),
retrogradely labeled cells were most prominent within the lateral and ventrolateral
regions of PAG. At the caudal pole of PAG (Bregma –8.80), retrograde labeling was
primarily localized within the dorsal half of PAG, with a few scattered cells present in the
ventrolateral region.
Although there were no differences in the overall distribution pattern of retrogradely
labeled cells for males and females, sex differences in the actual number of FG positive
cells were evident at all rostrocaudal levels of PAG. For example, at mid-levels of PAG
(Bregma –7.64), the mean number of FG+ cells in the lateral/ventrolateral region was
109 + 13 for males, in comparison to 142 + 15 for females. More caudally (Bregma –
8.30), the mean number of retrogradely labeled cells within the lateral/ventrolateral PAG
was 32% higher in females (175 + 19) in comparison to males (133 + 14). An ANOVA
on the number of FG labeled cells revealed significant main effects for sex
(F(1,248)=26.10, p<0.01), PAG subdivisions (F(1, 248)=27.40, p<0.01) and a significant
subdivisions by rostrocaudal level interaction (F(5,248)=12.10, p<0.01). A significant
interaction between level and subdivisions was expected based on previous studies
demonstrating shifts in the regional distribution of PAG-RVM output neurons that are
dependent on the rostrocaudal level of PAG (Bandler and Shipley, 1994).
The observed sex differences in the number of PAG-RVM output neurons was not due
to sex differences in FG transport rates; the number of FG+ cells retrogradely labeled
from the RVM within layer 5 of the motor/somatosensory cortex was comparable for
males and females ((F(1,8) = .009, p>0.05); Figure 2.3). Sex differences in retrograde
labeling are not due to differences in the area of the PAG for males and females; no
21

significant differences were noted in the mean area (mm2) for males in comparison to
females (F(1, 48)=1.70, p>0.05).
Sexually Dimorphic Activation of the PAG-RVM Circuit
The results from the above studies demonstrate that the PAG-RVM circuit is sexually
dimorphic in its anatomical organization, with females having significantly more PAGRVM output neurons than males. The next series of experiments was conducted to
determine if the activation of the PAG-RVM circuit by persistent inflammatory pain was
comparable for males and females. Intraplantar injection of CFA induced extensive Fos
expression throughout the rostral-caudal axis of PAG (Figure 2.4). Fos+ cells were
distributed throughout all regions of the PAG with no sex differences noted in the
distribution; similarly, an ANOVA revealed no significant main effect of sex in the
number of Fos+ cells induced by intraplantar CFA (F(1,107)=0.02, p>0.05).
While no significant differences were noted in the overall number of Fos+ cells for males
versus females, the number of PAG-RVM output neurons that expressed CFA-induced
Fos was significantly greater in males in comparison to females. Figure 2.5 shows the
distribution of PAG cells retrogradely labeled from the RVM that co-expressed CFAinduced Fos and an example of CFA-induced Fos and retrograde labeling from the
RVM in the male is presented in Figure 2.6. At all rostrocaudal levels of PAG, and within
all regions analyzed, dual labeled cells were more prevalent in males in comparison to
females. An ANOVA on the number of dual labeled neurons revealed significant main
effects for sex (F(1,108)=39.30, p<0.01), PAG subdivisions (F(1,108)=23.50, p<0.01)
and level (F(5,108)=2.20, p<0.05). In addition, a significant levels by subdivision
interaction was noted (F(5,108)=6.50, p<0.01); no other interactions reached
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significance (p>0.05).While FG/Fos+ cells were distributed within the dorsomedial and
lateral/ventrolateral regions of PAG, sex differences in the activation of the PAG-RVM
circuit were most evident within the lateral/ventrolateral PAG, where in males,
approximately 50% of all PAG-RVM output neurons expressed Fos, in comparison to
approximately 20% in females (Figure 2.7). An indication of the degree of variability in
the percentile data is shown in Figure 10.
As females had significantly more FG+ cells in comparison to males (see Figure 2.2),
we also determined the percentage of CFA-induced Fos+ cells that were present in
PAG-RVM cells. As no differences were noted in the number or distribution of Fos in
males versus females (see Figure 2.4), this would provide an indication of the
percentage of PAG cells activated by persistent inflammatory pain that were localized in
PAG-RVM output neurons. As shown in Figure 2.8, CFA-induced Fos preferentially
engaged a higher percentage of PAG-RVM output neurons in males in comparison to
females. An indication of the degree of variability in the percentile data is shown in
Figure 2.11. Similar to what was noted in Figure 2.5, this held true for all rostrocaudal
levels of PAG and for each region examined. Together, these data indicate that while
females have significantly more PAG-RVM output neurons, this circuit is preferentially
engaged in males in comparison to females during persistent pain states.
Morphine differentially suppresses persistent pain-induced activation of PAG-RVM
neurons
The above studies demonstrate that while persistent inflammatory pain activates a
comparable number of PAG neurons in males and females, PAG-RVM output neurons
were activated to a greater degree in males in comparison to females. The next series
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of experiments examined the ability of morphine to suppress CFA-induced Fos in males
versus females. Systemic morphine administration (4.5mg/kg, s.c.) attenuated CFAinduced Fos at all rostrocaudal levels of PAG in males (Figure 2.9); by contrast,
comparable numbers of CFA-induced Fos+ cells were noted for saline versus morphine
treated females. An ANOVA revealed significant main effects of sex (F(1,225)=5.70,
p<0.05), treatment (F(1, 225)=20.84, p<0.01), PAG subdivision (F(1, 225)=16.65,
p<0.01, and level (F(5, 225)=5.06, p<0.01). In addition, a significant sex by treatment
interaction was noted (F(1, 225)=4.72, p<0.05). Across all levels, morphine
administration resulted in a 26%-46% reduction in Fos expression in males; by contrast
only a 0-19% reduction in the number of Fos+ cells was noted in females.
We next examined if morphine was preferentially acting on PAG-RVM neurons to
suppress CFA-induced Fos. Figure 2.10 shows the percentage of PAG-RVM output
neurons that expressed CFA-induced Fos following administration of either saline or
morphine (4.5 mg/kg, s.c.) for males and females. An ANOVA on the number of
FG+Fos labeled cells revealed significant main effects of sex (F(1,228)=60.57, p<0.01),
treatment (F(1,228)=44.78, p<0.01), and PAG subdivision (F(1,228)=21.32, p<0.01), as
well as a significant sex by treatment interaction (F(1,228)=8.15, p<0.01. In addition, a
significant treatment by PAG subdivision by level interaction was noted (F(5,228)=2.42,
p<0.05), indicating that the effect of morphine on CFA-induced Fos in PAG-RVM output
neurons was variable and both level- and region-dependent. For example, in males,
morphine administration reduced the percentage of dual labeled cells in both the
dorsomedial and lateral/ventrolateral PAG within the rostral pole of PAG (-6.72). More
caudally, morphine administration either had no effect or actually increased the
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percentage of dual labeled cells in the dorsomedial PAG in comparison to saline treated
animals. Similar level- and region-dependent effects were noted for the
lateral/ventrolateral PAG. In females, the percentage of PAG-RVM neurons that
expressed CFA-induced Fos following morphine administration was comparable across
levels.
As morphine significantly reduced the number of CFA-induced Fos+ neurons in males
but not females, comparing the percent change in the activation of the PAG-RVM circuit
(%FG that contained Fos) for morphine versus saline treated males and females is
potentially biased. Therefore, we also examined the percentage of Fos+ neurons that
were present in PAG-RVM neurons (%Fos in FG neurons) following morphine or saline
treatment. A decrease in the %Fos present in PAG-RVM output neurons would suggest
that the observed morphine-induced decreases in Fos expression (see Figure 2.4) were
due to an inhibitory action on PAG-RVM output neurons. By contrast, if morphine was
primarily acting on intrinsic PAG neurons, then the percentage of Fos present in FG+
neurons should be comparable for morphine and saline treated animals or increased in
morphine treated animals, presumably due to the removal of a tonic inhibitory influence.
The results are presented in Figure 2.11. Similar to what was noted in Figure 2.10, the
effects of morphine on CFA-induced Fos in PAG-RVM neurons was variable across
levels and PAG regions. For example, within the lateral/ventrolateral region of PAG of
males, morphine increased (Bregma –8.00), decreased (Bregma –8.30) or had no effect
(Bregma –8.80) on the percentage of Fos localized in PAG-RVM neurons. In females,
the percentage of Fos present in PAG-RVM neurons was comparable for saline versus
morphine treated animals. Together, these results suggest the influence of multiple
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mechanisms of morphine action on persistent pain induced Fos, or alternatively, natural
variability across PAG regions and levels.

2.5 DISCUSSION
There are now well-established sex differences in the analgesic effects of morphine;
however, the CNS mechanisms underlying the sexually dimorphic actions of morphine
are unknown. As the PAG, and its descending projections to the RVM, constitute an
essential circuit for opioid analgesia, the present studies were conducted to determine if
the PAG-RVM pathway is sexually dimorphic in its anatomical organization and in its
activation during persistent inflammatory pain. The results of the present study
demonstrate profound sex differences in both the anatomical and functional
organization of the PAG-RVM pathway. The action of morphine on PAG neurons was
also found to be sexually dimorphic. Together, these results suggest that the PAG-RVM
pathway may provide an anatomical basis for observed sex differences in morphine
analgesia.
Sexually Dimorphic PAG-RVM Circuit: Functional Implications
Retrograde tracer injection into the RVM produced dense retrograde labeling within the
dorsomedial, lateral and ventrolateral regions of PAG; these results are consistent with
previous anatomical studies characterizing PAG outputs to the medulla (van Bockstaele
et al., 1991). Interestingly, while no sex differences were noted in the distribution of
PAG-RVM output neurons, females had significantly more retrogradely labeled cells in
comparison to males. The most prominent sex difference in retrograde labeling was
observed within the lateral/ventrolateral region of the PAG, where at some rostrocaudal
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levels, females had almost twice the number of retrogradely labeled neurons in
comparison to males. These studies are the first to demonstrate a sexually dimorphic
organization of a primary endogenous pain pathway.
The lateral/ventrolateral region of PAG has been implicated in a variety of physiological
functions, including the cardiovascular regulation (Bandler et al., 1991; Murphy et al.,
1995b), initiation of the ‘fight or flight’ response (Bandler & Carrive, 1988a; Carrive et
al., 1988; Zhang et al., 1990a), vocalization (Larson & Kistler, 1984; Larson, 1985;
Zhang et al., 1994; Jurgens, 2002; Dujardin & Jurgens, 2005) and reproductive behavior
(McCarthy et al., 1991a; Ogawa et al., 1991; Ogawa et al., 1992; Murphy & Hoffman,
2001). In addition, this region is a critical site for both stimulation-produced and
morphine-induced analgesia (Reynolds, 1969; Behbehani & Fields, 1979; Fardin et al.,
1984a; b; Morgan et al., 1991; Morgan et al., 1992; Zhang et al., 1998). Given that
morphine produces a greater degree of analgesia in males in comparison to females
(Cicero et al., 1996a; Craft et al., 1996; Bartok & Craft, 1997; Cicero et al., 1997; Boyer
et al., 1998; Tershner et al., 2000; Barrett et al., 2001; Cepeda & Carr, 2003; Stoffel et
al., 2003; Stoffel et al., 2005; Wang & Murphy, 2005) and the PAG-RVM pathway is a
critical circuit for opioid analgesia, we had initially hypothesized that if this circuit was
sexually dimorphic, retrograde labeling from the RVM would be more prominent in
males in comparison to females. Therefore, subsequent experiments were conducted to
examine the ‘activation’ of this circuit by a persistent noxious stimulus.
Intraplantar injection of the bacterium Complete Freund’s adjuvant is a well-established
model of persistent inflammatory pain (Millan et al., 1988; Stein et al., 1988a). Twentyfour hours following injection, edema and hyperalgesia are present in the injected paw.
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We have previously used this model and reported no sex differences in either the
degree of edema produced by intraplantar CFA, or in the withdrawal latencies following
application of a noxious thermal stimulus (Loyd et al., 2005; Wang & Murphy, 2005).
Hyperalgesia in animal models of inflammatory pain is closely linked to activation of
PAG-RVM descending modulatory circuits (Morgan et al., 1991; Williams et al., 1995)
and involve both facilitation and inhibition of inflammatory pain (Guan et al., 2002; Miki
et al., 2002; Ren & Dubner, 2002; Guan et al., 2003). In the present study, persistent
inflammatory pain induced extensive Fos expression throughout the rostrocaudal axis of
the PAG, indicating comparable activation of the PAG in males and females.
Interestingly, while no differences were noted in either the number or distribution of Fos
between males and females, persistent inflammatory pain preferentially activated the
PAG-RVM circuit in males and not females. Thus, while females have almost twice the
number of PAG-RVM output neurons in comparison to males, this descending
modulatory circuit is not being ‘engaged’ to the same degree by persistent inflammatory
pain in both sexes. As activation of the PAG and its descending outputs to the RVM
inhibits dorsal horn neuronal responses to acute noxious stimuli (Carstens et al., 1979;
Gray & Dostrovsky, 1983; Aimone et al., 1987; Jones & Gebhart, 1988; Waters & Lumb,
1997; Budai & Fields, 1998), the results of the present study may account for reported
sex differences in nociceptive thresholds (Berkley, 1997; Fillingim, 2000; Fillingim &
Ness, 2000; Barrett et al., 2002).
The adaptive significance of a sexually dimorphic PAG-RVM circuit is not clear. As
mentioned above, the PAG is involved in a variety of physiological functions, and in
females, this region is essential for the display of lordosis, the primary motor component
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of female reproductive behavior (McCarthy et al., 1991a; Ogawa et al., 1991).
Electrolytic lesions of the PAG, or direct administration of GABA antagonists,
significantly attenuate lordosis, while stimulation of this region facilitates it (Sakuma &
Pfaff, 1979a; b; 1980; McCarthy et al., 1991a; Kondo et al., 1993). In addition,
stimulation of the PAG has been shown to provide excitatory drive over RVM premotoneurons that innervate the axial muscles necessary for the display of lordosis
(Cottingham et al., 1987; 1988). Together, this suggests that in females, PAG outputs to
the RVM may be specialized for the modulation of somatosensory information essential
for the appropriate display of lordosis (Rose, 1975; Robbins et al., 1990; Robbins et al.,
1992), and specifically, may serve to increase somatosensory thresholds during
reproductive behavior (Crowley et al., 1976; Whipple & Komisaruk, 1985; Komisaruk &
Whipple, 1986). In support, the PAG receives extensive projections from the
lumbosacral spinal cord (Vanderhorst et al., 1996; Mouton et al., 2005), and spino-PAG
afferents terminate preferentially in PAG regions containing dense retrograde labeling
from the RVM (Murphy, unpublished observations). Therefore, activation of the
lumbosacral spinal cord by peripheral afferents during mounting by a male may function
to activate the PAG-RVM inhibitory pathway, thereby increasing sensory thresholds and
allowing for appropriate postural adjustments necessary for successful intromission by
the male.
Sexually Dimorphic Effect of Opiates on the PAG-RVM Circuit
Systemic morphine administration significantly attenuated CFA-induced Fos in males,
but not females. These results are consistent with previous studies reporting significant
sex differences in the antihyperalgesic effects of systemic morphine in persistent pain
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models (Cook & Nickerson, 2005; Wang & Murphy, 2005). Interestingly, while morphine
clearly suppressed CFA-induced Fos in males, the effect of morphine on Fos
expression in PAG-RVM neurons was highly variable. Indeed, depending on the PAG
region and rostrocaudal level, administration of morphine either increased, decreased,
or had no effect on the percentage of PAG-RVM neurons expressing Fos (%FG/Fos) in
comparison to saline-treated animals. Similarly, analysis of the percentage of Fos
present in FG neurons (%Fos/FG) following morphine or saline treatment provided no
additional clear insight. Two primary mechanisms have been proposed to account for
morphines’ action in the PAG. First, morphine has been shown to hyperpolarize
GABAergic interneurons that are presynaptic to PAG-RVM output neurons; this
hyperpolarization results in the disinhibition of PAG output neurons to the RVM resulting
in a net excitatory effect (Behbehani & Fields, 1979; Yaksh & Tyce, 1979; Cheng et al.,
1986; Moreau & Fields, 1986; Chieng & Christie, 1994a; Commons et al., 2000a;
Tortorici & Morgan, 2002). In the present study, this mechanism of morphine action
would be reflected as a decrease in Fos expression in intrinsic (presumably GABAergic)
neurons. The removal of tonic GABAergic inhibition would result in the net activation of
PAG-RVM neurons, thereby inducing Fos and increasing the percentage of Fos/FG
neurons in morphine treated animals in comparison to saline.
Morphine has also been shown to directly inhibit PAG-RVM neurons (Osborne et al.,
1996a). Anatomical studies by Commons et al. (2002) and Wang and Wessendorf
(Wang & Wessendorf, 2002) estimated that between 27-50% of PAG neurons
retrogradely labeled from the RVM contain MOR; these dual labeled cells were localized
primarily within the caudal lateral/ventrolateral PAG. In the present study, a direct
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inhibitory mechanism of morphine action would be reflected as a decrease in the
percentage of FG+Fos labeled cells following opioid administration.
A precise mechanism of morphine action (presynaptic versus direct) cannot be
discerned in the present study, and the results suggest that both mechanisms
contributed to the suppression of persistent pain induced Fos in the PAG of males. The
variability noted in the action of morphine on PAG-RVM neurons is not easily
attributable to level and region-dependent differences in PAG mu opioid receptor
expression. Mu opioid receptors are localized throughout the rostral-caudal axis of PAG,
with low to moderate levels of expression noted in the rostral two-thirds of PAG
(Bregma –6.72 to –8.00) (Duncan and Murphy, 2005). The highest level of MOR
expression is within the caudal ventrolateral PAG (Bregma –8.30 to -8.80), and in the
present study, the effects of morphine on Fos expression in PAG-RVM neurons were
quite variable at this level.
It is important to consider that while lesions of the PAG or intra-PAG naloxone
significantly attenuate the effects of systemic morphine, they do not block it completely.
This suggests the involvement of additional loci, including both central (Jensen &
Yaksh, 1986; Heinricher et al., 1994) and peripheral (Stein et al., 1988b) sites of
morphine action. Thus, in addition to a direct action within the PAG, morphine would
also reduce incoming noxious input to the spinal cord at the primary afferent synapse,
which would ultimately reduce noxious stimulus-induced Fos in PAG.
There was no effect of morphine on CFA-induced Fos in females. These results concur
with our recent data indicating that the ED50 for either systemic (Loyd et al., 2005) or
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intra-PAG (Loyd et al., 2005) morphine is approximately two times higher in females
than males in a model of persistent inflammatory pain. Similar findings for intra-PAG
morphine administration have been reported in studies utilizing acute pain models
(Rossi et al., 1994; Krzanowska & Bodnar, 1999; 2000).
Interestingly, recent studies report that systemic morphine simultaneously activates both
pain inhibitory as well as pain facilitatory systems (Vanderah et al., 2001a; Vanderah et
al., 2001b). Specifically, in rats, sub-analgesic doses of morphine (0.002-0.2 mg/kg)
result in a hyperalgesic response, and this effect is significantly more pronounced in
females than males (Holtman & Wala, 2005). While the mechanism(s) and neural
substrates underlying morphine-induced hyperalgesia are unknown, it is interesting to
speculate that in females, a low dose of morphine may concurrently activate both pain
facilitatory and inhibitory circuits within the PAG, thereby resulting in no change in CFAinduced Fos. Further studies are obviously warranted.
Unfortunately, to date, all studies examining the antinociceptive mechanisms of
morphine action in the PAG have been conducted exclusively in males; therefore, it is
not known whether morphine administration has the same physiological effect on PAG
neurons in females. The PAG contains a large population of estrogen receptors (ERα)
(Murphy & Hoffman, 1999; Murphy & Hoffman, 2001), and in both males and females,
approximately 20-25% of PAG-RVM neurons contain ERα (Loyd & Murphy, 2004a).
Estrogen binding to its receptor within PAG-RVM neurons may be involved in liganddependent transcriptional events, thereby influencing the expression of various
neurotransmitters and/or membrane properties (Zakon & Dunlap, 1999). Alternatively,
as the gene encoding Fos contains an estrogen response element (Loose-Mitchell et
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al., 1988; Wang et al., 2003), changes in cycle status may have potentially influenced
the effect of morphine on CFA-induced Fos in females, particularly if the animals were
in similar stages of estrous. In the present study, the phase of the estrous cycle was not
determined. However, if cycle status differentially affected Fos expression, then the
degree of variability in CFA-induced Fos should be greater in females in comparison to
males; however, this was not observed in the present study.
Alternatively, the mu opioid receptor is a member of the inhibitory G protein-coupled
receptor superfamily, and in hypothalamic slices, estrogen has been shown to rapidly
uncouple the mu receptor from G protein-gated inwardly rectifying potassium channels
resulting in a reduced hyperpolarization by MOR agonists (Kelly et al., 2003; Malyala et
al., 2005). Estrogen has also been shown to result in MOR internalization, thereby
limiting the amount of receptor available for exogenous ligand binding (Eckersell et al.,
1998a). Lastly, we have recently reported significant sex differences in mu opioid
receptor protein levels within the caudal lateral/ventrolateral PAG, with intact males
have 11% higher levels of MOR protein in comparison to diestrus females (Duncan &
Murphy, 2005). Together, these studies may provide several direct mechanisms for the
reduced potency of mu agonists noted in females.

2.6 CHAPTER SUMMARY
There are now well-established sex differences in the analgesic effects of morphine;
however, the CNS mechanisms underlying the sexually dimorphic actions of morphine
are unclear. The PAG, and its descending projections to the RVM and dorsal horn of the
spinal cord, constitute an essential neural circuit for opioid-based analgesia. The results
33

of the present study demonstrate for the first time that the PAG-RVM pathway is
sexually dimorphic in its anatomical organization and in its activation during persistent
inflammatory pain. The actions of morphine on PAG neurons are also sexually
dimorphic. Together, these results suggest that the PAG-RVM pathway may provide an
anatomical basis for observed sex differences in morphine analgesia.
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Figure 2.1. Representative examples of FG injection localization in the RVM of a male
(top) and female (bottom) rat. Scale bar: 200µm.
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Figure 2.2. Distribution of cells retrogradely labeled from the rostral ventromedial
medulla in males and females at six rostrocaudal levels of the periaqueductal gray.
Each black circle represents one FG-immunoreactive cell. Bar graphs show the mean
number (+ S.E.M.) of FG-immunoreactive cells for the dorsomedial and
lateral/ventrolateral regions of PAG.
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Figure 2.2 continued
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Figure 2.3. Photomicrographs of cortical retrograde labeling following tracer injection
into the RVM in the male (A) and female (B) rat (Bregma –1.0). Scale bar: 200µm. Bar
graph (C) shows the mean number (+ S.E.M.) of retrogradely labeled cells in the cortex
of males and females. Labeling was localized to pyramidal cells in layer 5. Dorsal
counts include primarily motor cortex, while ventral counts are primarily somatosensory
cortex.
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Figure 2.4. Distribution of CFA induced Fos within the periaqueductal gray of males
and females across six rostrocaudal levels. Each black circle represents one Fos+ cell.
No sex differences were noted in either the distribution or number of Fos+ cells for
males and females.

39

Figure 2.5. Distribution of PAG-RVM output neurons that expressed CFA-induced Fos
for males and females across six rostrocaudal levels of the PAG. Each black circle
represents one double-labeled (FG+Fos) cell. Bar graphs display the mean number of
FG/Fos cells (+ S.E.M.) for each level and region.
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Figure 2.5 continued
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Figure 2.6. Color photomicrograph showing a low (A) and high (B) power example of
single and double labeled Fos and FG labeled cells in the PAG of a male rat. Scale bar
= 100 µm in panel A; scale bar = 50 µm in panel B.
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Figure 2.7. Percentage of PAG-RVM neurons that were activated by persistent
inflammatory pain (FG+Fos) in males (left) and females (right) throughout the
rostrocaudal axis of PAG.
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Figure 2.8. Percentage of Fos+ PAG neurons that were retrogradely labeled from the
RVM (Fos+FG) in males (left) and females (right) throughout the rostrocaudal axis of
PAG.
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Figure 2.9. Distribution of CFA-induced Fos (black dots) following saline (black) or
morphine (white) administration in males (left) and females (right) along the
rostrocaudal axis of PAG. Each black circle represents one Fos+ cell. Bar graphs show
mean number of Fos+ cells (+ S.E.M.) for each treatment group broken down
separately for the dorsomedial and lateral/ventrolateral PAG.
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Figure 2.9 continued
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Figure 2.10. Percentage of PAG-RVM neurons expressing CFA-induced Fos
(%FG/Fos) following saline (black bars) or morphine (4.5 mg/kg; s.c.; white bars) in
male (left) and female (right) rats for six rostrocaudal levels of PAG.
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Figure 2.11. Percentage of CFA-induced Fos positive neurons that were retrogradely
labeled from the RVM (%Fos/FG) following saline (black bars) or morphine (4.5 mg/kg;
s.c.; white bars) in male (left) and female (right) rats for six rostrocaudal levels of PAG.
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3.1 ABSTRACT
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral
ventromedial medulla (RVM) provide an essential neural circuit for opioid-produced
antinociception. Recent anatomical studies have reported that the projections from the
PAG to the RVM are sexually dimorphic and that systemic administration of morphine
significantly suppresses pain-induced activation of the PAG in male but not female rats.
Given that morphine antinociception is produced in part by disinhibition of PAG output
neurons, it is hypothesized that a differential activation of PAG output neurons mediates
the sexually dimorphic actions of morphine. The present study examined systemic
morphine-induced activation of PAG-RVM neurons in the absence of pain. The
retrograde tracer fluorogold (FG) was injected into the RVM to label PAG-RVM output
neurons. Activation of PAG neurons was determined by quantifying the number of Fospositive neurons one hour following systemic morphine administration (4.5 mg/kg).
Morphine produced comparable activation of the PAG in both male and female rats,
with no significant differences in either the quantitative or qualitative distribution of Fos.
While microinjection of FG into the RVM labeled significantly more PAG output neurons
in female rats than male rats, very few of these neurons (20%) were activated by
systemic morphine administration in comparison to males (50%). The absolute number
of PAG-RVM neurons activated by morphine was also greater in males. These data
demonstrate widespread disinhibition of PAG neurons following morphine
administration. The greater morphine-induced activation of PAG output neurons in male
compared to female rats is consistent with the greater morphine-induced antinociception
observed in males.
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3.2 INTRODUCTION
Morphine and other mu-opioid receptor agonists are the most effective pharmacological
treatment for the alleviation of persistent pain. However, morphine does not produce the
same degree of analgesia in males and females. In the majority of studies reported to
date, morphine produced a greater antinociceptive response in males compared to
females (Bodnar et al., 1988a; Craft, 2003b; a; Cook & Nickerson, 2005; Wang et al.,
2006). Sex differences in morphine analgesia have been reported in studies employing
orofacial (Okamoto et al., 2005), somatic (Bartok & Craft, 1997; Cicero et al., 1997;
Boyer et al., 1998; Kest et al., 1999; Barrett et al., 2001) or visceral (Ji et al., 2006; in
press) pain models. To date, the mechanism(s) whereby morphine produces a
differential degree of analgesia is unclear.
The midbrain periaqueductal gray (PAG), and its descending projections to the rostral
ventromedial medulla (RVM) and spinal cord, comprises an essential neural circuit for
both endogenous and exogenous opioid-mediated analgesia (Basbaum et al., 1978;
Basbaum & Fields, 1978; Basbaum & Fields, 1984). The PAG contains a high density
of mu opioid receptors (Commons et al., 1999; Commons et al., 2000b; Wang &
Wessendorf, 2002) and microinjection of opioid antagonists into the PAG significantly
attenuates systemic morphine-produced analgesia (Zambotti et al., 1982; Randich et
al., 1992; Lane et al., 2005; Bernal et al., 2007). Similarly, microinjection of the mu
opioid selective neurotoxin dermorphin-saporin (Porreca et al., 2001; Burgess et al.,
2002; Vera-Portocarrero et al., 2006a; Vera-Portocarrero et al., 2006b) into the PAG
significantly attenuates systemic morphine analgesia (Loyd & Murphy, 2007a).
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Together, these studies indicate that the PAG is a primary neural structure for opioidmediated analgesia.
Recent studies have reported sex differences in both the anatomical and physiological
organization of the PAG-RVM pathway. These sex differences may provide the
biological bases for the observed sexually dimorphic actions of morphine. For example,
recent anatomical studies have shown that females have a significantly greater number
of PAG neurons retrogradely labeled from the RVM in comparison to males.
Interestingly, persistent inflammatory pain only activates this pathway in males.
Similarly, systemic morphine administration decreases noxious stimulus-induced
activation of the PAG in male but not female rats (Loyd & Murphy, 2006). Together,
these studies suggest a sexually dimorphic action of morphine within the PAG. This
suggestion is further supported by studies showing that microinjection of morphine into
the PAG produces greater antinociception in male in comparison to female rats
(Krzanowska & Bodnar, 1999; Bernal et al., 2007; Wang et al., submitted).
Electrophysiological studies have reported that morphine, as well as other opioid
agonists, inhibit and excite different populations of PAG neurons. In vitro recordings
have shown that opioids disinhibit PAG-RVM output neurons by presynaptically
inhibiting tonically active GABAergic neurons (Behbehani et al., 1990a; Behbehani et
al., 1990b; Chieng & Christie, 1994a; Stiller et al., 1995). This GABA-mediated
disinhibition results in the activation of PAG-RVM neurons. However, other studies have
shown that opioids directly inhibit a subset of PAG-RVM projection neurons (Chieng &
Christie, 1994a; Osborne et al., 1996b), and mu opioid receptors have been localized
on approximately 27-50% of PAG neurons retrogradely labeled from the RVM
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(Commons et al., 2000b; Wang & Wessendorf, 2002). If GABA disinhibition is the
primary mechanism for morphine action in the PAG, then administration of morphine
should preferentially induce Fos in PAG-RVM output neurons. By contrast, if morphine
antinociception is primarily mediated via direct inhibition of PAG-RVM output neurons,
then systemic administration of morphine should not induce Fos in these neurons as
Fos induction requires membrane depolarization (Greenberg et al., 1986a; Greenberg
et al., 1986b; Bartel et al., 1989).
The present studies were conducted to determine whether morphine administration
preferentially activates PAG-RVM output neurons using retrograde tract tracing in
combination with Fos immunocytochemistry. Morphine-induced Fos in PAG-RVM output
neurons was compared in male and females rats to determine if there were qualitative
or quantitative sex differences in activation of this pathway in the absence of persistent
pain. If sex differences in the PAG-RVM circuit provide the basis for the sexually
dimorphic actions of morphine, then activation of this pathway should be greater in male
compared to female rats when given the same dose of morphine.

3.3 METHODS
Subjects
Adult male and weight-matched (250-350g) cycling female Sprague-Dawley rats (ZivicMiller; Pittsburg, PA) were used. Rats were housed in same-sex pairs in separate
rooms on a 12:12 hour light: dark cycle (lights on at 7:00A.M.). Access to food and water
was ad libitum throughout the experiment except during surgery. Vaginal lavages were
taken daily to determine if the female rats were cycling normally and to keep daily
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records on the stages of their cycle in respect to the experimental testing. These
studies were performed in compliance with the Institutional Animal Care and Use
Committee at Georgia State University.
Retrograde Tracer Injections
Six male and six female rats were deeply anesthetized with ketamine/xylazine (50
mg/kg / 10mg/kg; s.c.) and placed in a stereotaxic frame. The position of the skull was
adjusted so that bregma and lambda were at the same dorsal-ventral plane. Glass
micropipettes (10-20 µM) filled with the retrograde tracer Fluorogold (FG; 2% soln. w/v
in saline; Fluorochrome LLC; Denver, CO) were lowered into the RVM using the
following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0; DV: -8.5. FG was
iontophoresed (50/50 duty cycle, 7.5 µA current) into the RVM for 25 minutes to
facilitate neuronal uptake. The current was then turned off, and the pipettes remained
in place for an additional 5 minutes to reduce backflow of tracer along the pipette track.
Only males and females that had comparable injection sites were used for data
collection. Following tracer injections, wounds were sutured closed, the antibiotic
Neosporin was applied to the wound, and the animals were placed in clean cages to
recover under a heat lamp. Upon complete recovery from the anesthetic, animals were
returned to their original housing facilities.
Morphine Administration
All animals were given a subcutaneous injection of either morphine sulfate (4.5 mg/kg,
s.c.; NIDA; Bethesda, MD) or sterile saline as a control. All injections were performed
between the hours of 12:00P.M. and 2:00P.M. Morphine sulfate was prepared fresh in a
saline vehicle within one hour prior to injection.
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Perfusion fixation
One hour after morphine administration, animals were given a lethal dose of Nembutal
(160 mg/kg; i.p.). The animals were transcardially perfused with 150-200 ml of 0.9%
sodium chloride containing 2% sodium nitrite as a vasodilator, to remove blood from the
brain. Immediately following removal of blood, 300 ml of 4% paraformaldehyde in 0.1M
phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused
through the brain as a fixative. A final rinse with 150-200 ml of the sodium
chloride/sodium nitrate solution was perfused through the brain to remove any residual
acrolein. Immediately following perfusion, the brains were carefully removed, placed in
a 30% sucrose solution and stored at 40C for at least one week prior to sectioning. To
section the brain, the dura and pia mater were carefully removed and the brains were
cut into six series of 25 µm coronal sections with a Leica 2000R freezing microtome and
stored free-floating in cryoprotectant-antifreeze solution (Watson et al., 1986b) at –20oC
until immunocytochemical processing.
Immunocytochemistry
A 1:6 series through the rostrocaudal axis of each brain was processed for FG and/or
Fos immunoreactivity as previously described (Murphy & Hoffman, 2001). Briefly,
sections were rinsed extensively in potassium phosphate-buffered saline (KPBS) to
remove cryoprotectant solution immediately followed by a 20-minute incubation in 1%
sodium borohydride to remove excess aldehydes. The tissue was then incubated in
primary antibody solution(s) previously described (Loyd & Murphy, 2006): rabbit antiFos (Oncogene; Cambridge, MA, lot no. 4194; 1:50,000) and/or rabbit anti-FG
(Chemicon; Billerica, MA, lot no. 25060005; 1:10,000) in KPBS containing 1.0% Triton-X
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for one hour at room temperature followed by 48 hours at 4°C. After rinsing out the
primary antibody with KPBS, the tissue was incubated for one hour in biotinylated goat
anti-rabbit IgG (Jackson Immunoresearch; West Grove, PA, 1:200), rinsed with KPBS,
followed by a one hour incubation in an avidin-biotin peroxidase complex (1:10; ABC
Elite Kit, Vector Labs). After rinsing in KPBS and sodium acetate (0.175 M; pH 6.5),
Fos was visualized as a black reaction product using nickel sulfate intensified 3,3’diaminobenzidine solution containing 0.08% hydrogen peroxide in sodium acetate
buffer. FG was visualized as a brown reaction product using 3,3’-diaminobenzidine
containing 0.08% hydrogen peroxide in Trizma buffer (pH 7.2). After 15-30 minutes,
three rinses in sodium acetate buffer terminated the reaction. Sections were then
mounted out of saline onto gelatin-subbed slides, air-dried overnight, dehydrated in a
series of graded alcohols, cleared in xylene, and cover-slipped using Permount.
Data Analysis and Presentation
The number of PAG-RVM output neurons (FG+), the number of activated intrinsic PAG
neurons (Fos+), and the number of activated PAG-RVM output neurons (Fos+FG) was
determined across six rostrocaudal levels of PAG (Bregma -6.72, -7.04, -7.74, -8.00, 8.30, -8.80). The experimenter was blind to the experimental condition. Neurons were
counted in two PAG subdivisions: dorsomedial and lateral/ventrolateral; these
subdivisions are clearly distinguishable based on the distribution of retrograde labeling
from the RVM (van Bockstaele et al., 1991; Bandler & Shipley, 1994b). The
lateral/ventrolateral region was counted unilaterally as there are no differences in the
number of FG+ cells for the left versus right side of PAG (Loyd & Murphy, 2006). There
are no cytoarchitectural or anatomical boundaries between the lateral and ventrolateral
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regions; therefore, these regions were counted together to avoid experimenter bias. The
tissue was sectioned at 25µm so that 125µm separated each analyzed level of the PAG
thus avoiding any bias of counting the same cell twice. Additionally, previous data have
shown that there are no sex differences in the mean area (mm2) of PAG between
weight-matched male and female Sprague-Dawley rats (Loyd & Murphy, 2006).
Data are expressed as the mean + standard error of the mean (SEM) from which
percentages were calculated. A four-way analysis of variance (ANOVA) was used to
test for significant main effects of sex (male, female), PAG subdivision (dorsomedial,
lateral/ventrolateral), PAG level (Bregma –6.72 through -8.80) and treatment (morphine,
saline). P<0.05 was considered significant for all analyses. For data presentation, a
representative animal from each experimental group was selected and the distribution
of FG and Fos within the PAG were plotted using a Nikon Drawing Tube attached to a
Nikon Optiphot microscope. Plots were then scanned onto the computer and adjusted to
figure format using Adobe Illustrator 10. Photomicrographs were generated using a
Synsys digital camera attached to a Nikon Eclipse E800 microscope. Images were
captured with IP Spectrum software, adjusted to figure format by adjusting brightness
and contrast levels using Adobe Photoshop 7.0.

3.4 RESULTS
Systemic Morphine-Induced Activation of the PAG
The objective of the present experiment was to examine if morphine activation of the
PAG is quantitatively and/or qualitatively different in male and female rats. Animals
were given a systemic injection of either morphine (4.5 mg/kg, s.c.; n=6/sex) or sterile
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saline (n=5 males and n=6 females) and perfused one hour later. The distribution and
number of neurons expressing Fos were determined across six rostrocaudal levels of
the PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80) and within the dorsomedial
and lateral/ventrolateral regions.
In animals treated with systemic morphine, Fos+ cells were primarily distributed
throughout the dorsomedial, lateral and ventrolateral regions of the PAG with very little
Fos in the dorsolateral or ventromedial regions (see Figure 3.1). The quantity and
distribution of Fos labeled neurons was relatively consistent across the rostrocaudal
axis of the PAG (Bregma –6.72 to –8.80 mm) and was almost two-fold greater in
morphine treated animals in comparison to saline control [F(1,252) = 106.7, p < 0.0001].
In animals treated with morphine, the mean number of Fos+ cells in the rostral PAG was
77.5 + 13.4 in comparison to 25 + 8 in saline treated animals. Caudally (Bregma -8.30),
the mean number of Fos+ cells in morphine treated animals was 78 + 3 versus 33 + 7
for saline control. Morphine administration induced comparable Fos expression in the
PAG in both male and female rats [F (1,252) = 1.60, p > 0.05]. For example, at rostral
levels of PAG (Bregma -7.04), the mean number of Fos+ cells was 73 + 16 for males, in
comparison to 77 + 13 for females. More caudally (Bregma -8.30), the mean number of
Fos+ cells was 78.3 + 14 in males in comparison to 81 + 12 in females.
Sexually Dimorphic Activation of the PAG-RVM Circuit by Morphine
The results from the first set of experiments demonstrate that acute morphine
administration induces greater activation of the PAG compared to acute saline
administration, and that this activation is comparable in male and female rats. The
objectives of the next experiment were to determine (1) whether morphine preferentially
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activates PAG-RVM output neurons, and (2) if this activation is sexually dimorphic.
Animals received Fluorogold injections into the RVM; ten days later they were injected
with either systemic morphine (4.5 mg/kg; n=5 per sex) or sterile saline (n=5 males and
n=6 females) and perfused one hour later.
Figure 3.2 shows an example of a typical iontophoretic injection of FG into the RVM of a
male (top) and female (bottom). All injections were located on the midline and dorsal to
the pyramidal tract, at the level of the caudal pole of the facial nucleus (lambda –
2.0mm). Injections outside of the RVM were not included for analysis. Injection of FG
into the RVM produced dense retrograde labeling across the rostrocaudal axis of the
PAG in both male and female rats. As reported previously (Loyd & Murphy, 2006),
there were significantly more retrogradely labeled neurons across all rostrocaudal levels
of the PAG in female as compared to male rats [F (1,216) = 48.2, p < 0.0001]. Acute
systemic administration of morphine induced Fos labeling in a subset of PAG output
neurons in both male and female rats. The number of activated PAG output neurons
was consistently higher in the PAG of male compared to female rats (Figure 3). For
example, at rostral levels of PAG (Bregma -6.72), the mean number of double-labeled
cells in the lateral/ventrolateral subdivision of the PAG was 18 + 4 for males, in
comparison to 6 + 1 for females. More caudally (Bregma -8.30), the mean number of
double-labeled cells in the lateral/ventrolateral subdivision of the PAG was 42 + 11 in
males, in comparison to 20 + 3 in females. This activation of output neurons was
significantly greater in male compared to female rats whether analyzed as number of
double labeled neurons [F(1,192) = 43.3, p < 0.0001] (Figure 3.3), percent of FG
labeled neurons expressing Fos [F(1,192) = 223.2, p < 0.0001] or percent Fos that was
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expressed in FG neurons [F(1,192) = 65.379, p < 0.0001] (Figure 3.4). The greater
mean number of Fos-positive PAG-RVM neurons in male rats is particularly noteworthy
given that the total number of projecting neurons is greater in female rats. The greater
number of double labeled neurons in male rats is evident in both dorsomedial and
lateral/ventrolateral regions across all rostrocaudal levels of the PAG (Figure 3.3).
The number of double-labeled cells also varied across PAG levels with caudal regions
showing greater label in the lateral/ventrolateral compared to dorsomedial subdivision
and rostral regions showing comparable labeling in the two subdivisions. An ANOVA on
the number of Fos+ neurons revealed a significant main effect of levels-by-subdivision
interaction [F(5,252) = 2.97, p < 0.05]; no other interactions reached significance (p >
0.05).

3.5 DISCUSSION
It is becoming increasingly evident that morphine produces a greater degree of
analgesia in males in comparison to females. To date, the mechanisms underlying sex
differences in morphine analgesia remain unknown. The PAG and its descending
projections to the RVM provide the primary circuit for opioid-produced analgesia, and
sex differences in the activation of this circuit by morphine would be predicted to
contribute to the reported sex differences in morphine analgesia. The results of our
studies demonstrate that systemic morphine administration induces extensive Fos
expression within the PAG of male and female rats. Interestingly, while no sex
differences were noted in the overall number or distribution of morphine-induced Fos,
morphine preferentially activated the PAG-RVM circuit in males. Indeed, at most rostral60

caudal levels of PAG, the percentage of PAG-RVM neurons expressing morphine
induced Fos was two-fold higher in males in comparison to females.
In the present study, the observed morphine-induced Fos may be due to direct actions
of morphine at the mu opioid receptor (MOR) or alternatively, due to secondary effects
associated with morphine administration, including changes in blood pressure,
respiration and cardiac output. These autonomic changes have been shown previously
to induce Fos expression within the PAG of the rat (Murphy et al., 1995a). However, as
pharmacological or neurotoxic blockade of MOR in the PAG significantly attenuates the
analgesic effects of systemic morphine, this suggests that the Fos observed in the
present study was primarily due to direct actions of morphine in the PAG. In support of
this, Fos expression was primarily localized within the dorsomedial and
lateral/ventrolateral PAG; these regions contain high levels of mu opioid receptor
(Commons et al., 2000b; Wang & Wessendorf, 2002; Wang et al., submitted).
Interestingly, mu opioid receptors are virtually absent in the dorsolateral PAG; similarly,
this region contained very little, if any, morphine-induced Fos.
The PAG-RVM Circuit is Preferentially Activated in Male Rats
Fluorogold injection into the RVM produced dense retrograde labeling within the
dorsomedial, lateral and ventrolateral divisions of the PAG, consistent with previous
anatomical studies in the rat (Beitz et al., 1983; van Bockstaele et al., 1991; Rizvi et al.,
1996). Interestingly, while the number of PAG neurons retrogradely labeled from the
RVM is almost two-fold higher in females in comparison to males, very few of these
PAG-RVM cells were activated following morphine administration (FG/Fos; overall
between 14-25% of FG+ cells). Similarly, although morphine induced comparable levels
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of Fos within the PAG of males and females, the percentage of Fos present in FG+ cells
(Fos/FG) was only between 14-25%. By contrast, in males, the percentage of FG+ cells
co-expressing Fos ranged between 48-77%, while the percentage of Fos+ cells labeled
with FG was between 34-54%. The results of the present study indicating that between
48-77% of PAG-RVM neurons in males express morphine-induced Fos, suggesting that
administration of morphine results primarily in the net excitation of PAG-RVM neurons,
most likely through removal of tonic GABA inhibition (Moreau & Fields, 1986; Behbehani
et al., 1990b; Vaughan & Christie, 1997; Commons et al., 2000b). Direct inhibition of
PAG-RVM neurons by morphine may also contribute to morphine analgesia and cannot
be ruled out in the present study.
Interestingly, while females had extensive Fos present in the PAG, very little Fos was
present in PAG output neurons. As activation of the PAG-RVM pathway is essential for
morphine-induced analgesia, these results provide a likely mechanism for sex
differences in morphine analgesia. It is not clear why females had such extensive Fos
expression overall in the PAG, but very little in RVM projection neurons. Unfortunately,
to date, no in vitro recordings have been conducted from female PAG slices so the
effects of morphine on the physiological properties of PAG neurons can only be inferred
from male data. Clearly, this needs to be addressed in the future. One possibility is that
in females, morphine activates a pain facilitation network. A PAG-RVM pain facilitatory
system has been shown to contribute to hyperalgesia produced by opiate withdrawal
(Bederson et al., 1990), chronic inflammation (Terayama et al., 2000; Guan et al.,
2002), and morphine tolerance (Vanderah et al., 2001b). Interestingly, morphine-
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induced hyperalgesia is significantly more pronounced in females in comparison to
males (Holtman & Wala, 2005).
Alternatively, there may be a sex difference in the organization or function of the
GABAergic system inhibiting the PAG cells involved in modulating nociceptive
transmission. Intra-PAG administered GABA antagonists block pain behaviors (Budai
and Fields, 1998; Moreau and Fields, 1986) and lead to depolarization, increased firing
frequency, and increased excitatory post-synaptic potentials in PAG neurons responsive
to GABA (Behbehani et al., 1990b). Intra-PAG GABA agonists (Moreau and Fields,
1986) and mu opioid receptor antagonists (Budai and Fields, 1998) reverse the
analgesic effects of the GABA antagonists and of morphine. While the ventrolateral
PAG contains a high density of mu opioid receptors, very few of the neurons that project
to the RVM are directly inhibited by opioid agonists (Osborne et al., 1996). In the
present study, males had greater activation of the PAG-RVM pathway by systemic
morphine, indicating that morphine is acting through local GABA neurons, whereas
females potentially have a different organization or function of this GABAergic system.
The present study used gonadally intact, cycling females and a number of studies have
suggested that gonadal steroids may influence morphine potency. For example,
treatment of female rat pups with androgen on the day of birth results in a leftward shift
of the morphine dose response curve (Krzanowska & Bodnar, 1999; Cicero et al., 2002;
Cataldo et al., 2005). In adulthood, ovariectomy increases morphine potency in female
rats and this effect is blocked by exogenous estradiol replacement (Negus & Mello,
1999; Stoffel et al., 2005; Ji et al., in press). Similarly, in males, castration decreases
and testosterone replacement restores morphine potency (Stoffel et al., 2005). The rat
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PAG contains a dense population of estrogen (ERα) and androgen (AR) receptor
containing neurons (Murphy & Hoffman, 1999; Murphy & Hoffman, 2001; Marson &
Murphy, 2006). These receptors are localized in similar regions of the PAG as the mu
opioid receptor and in our preliminary studies, we noted that a large proportion of PAGRVM neurons also contain ERα (Loyd & Murphy, 2004).
In hypothalamic slices, estrogen has been shown to rapidly uncouple the mu opioid
receptor from G protein-gated inwardly rectifying potassium channels resulting in a
reduced hyperpolarization by MOR agonists (Kelly et al., 2003). Estrogen-mediated
hyperpolarization of PAG-RVM neurons would provide a direct mechanism whereby
morphine failed to elicit Fos in PAG-RVM neurons. Alternatively, as the gene encoding
Fos contains an estrogen response element (Loose-Mitchell et al., 1988; Wang et al.,
2003), changes in cycle status may have potentially influenced the ability of morphine to
induce Fos in PAG-RVM neurons in females. Lastly, estradiol has also been shown to
induce MOR internalization (Eckersell et al., 1998b; Sinchak & Micevych, 2001;
Micevych et al., 2003; Mills et al., 2004); this would limit the amount of receptor
available for ligand binding and would thereby potentially decrease morphine’s ability to
induce Fos in PAG-RVM neurons. Future studies are necessary to further test these
potential mechanisms.

3.6 CHAPTER SUMMARY
The results of the present study indicate that morphine preferentially activates the PAGRVM pathway in males. These results concur with our previous study demonstrating
that persistent inflammatory pain selectively activates the PAG-RVM pathway in males,
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but not females. In that study, we also demonstrated that morphine preferentially
suppressed persistent pain induced Fos in males, but not females. Unfortunately, the
effects of morphine on persistent pain induced Fos in PAG-RVM output neurons was
quite variable, and it was unknown whether the effects we were observing were due to
morphine acting directly on PAG-RVM neurons and/or if morphine was decreasing paininduced drive to the PAG. In the present study, morphine was given in the absence of
pain and was shown to preferentially activate the PAG-RVM circuit in males. Indeed, at
most rostral-caudal levels of the PAG, the percentage of PAG-RVM neurons expressing
morphine-induced Fos was two-fold higher in males in comparison to females. As the
PAG-RVM circuit is essential for morphine analgesia, sex differences in the activation of
this pathway may provide the biological bases for the sexually dimorphic actions of
morphine.
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Figure 3.1. Distribution of morphine-induced Fos in male and female rats at six
rostrocaudal levels of the PAG. Each black circle represents one Fos-immunoreactive
cell. Bar graphs compare the mean number (+ S.E.M.) of Fos-immunoreactive cells in
male and female rats 1 hr after administration of morphine or saline. Morphine
administration induced a significant increase in the number of Fos labeled neurons
compared to saline. This increase was comparable in male and female rats.
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Figure 3.1 Continued
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Figure 3.2. Representative examples of FG injection localization in the RVM of a male
(top) and female (bottom) rat. All injections were along the midline and in the bottom
third of the medulla. Gi, gigantocellularis; 7, facial nucleus; py, pyramidal tract; 4V,
fourth ventricle.
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Figure 3.3. Distribution of PAG-RVM output neurons that expressed morphine-induced
Fos in male and female rats across six rostrocaudal levels of the PAG. Each black
circle represents one double-labeled (Fos+FG) cell. Bar graphs display the mean
number of Fos+FG cells (+ S.E.M.) for each level of the dorsomedial and
lateral/ventrolateral regions of the PAG. Overall, Fos labeling was greater in FG+ cells
in male versus female rats in PAG.
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Figure 3.3 continued
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Figure 3.4. Photomicrograph showing morphine-induced Fos in FG+ cells for males (A,
10X; B, 20X) and females (C, 10X; D, 20X). Note that while females have a greater
number of FG+ cells than males, very few of these cells expressed morphine-induced
Fos (indicated with red arrows). No sex differences were noted in the total number of
Fos+ cells.
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Figure 3.5. Percentage of morphine-induced Fos+ PAG neurons that were retrogradely
labeled from the RVM (Fos+FG) in male (left) and female (right) rats in the dorsomedial
and lateral/ventrolateral regions of the PAG at six representative levels. The proportion
of Fos positive neurons projecting to the RVM was greater in male than female rats
across all PAG regions.
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4.1 ABSTRACT
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral
ventromedial medulla (RVM) provide an essential neural circuit for the antinociceptive
effects of opiates and has been implicated in the development of tolerance to morphine.
Systemic morphine activates a greater proportion of PAG-RVM neurons in male versus
female rats and induces tolerance to a greater degree in males. The present studies
tested the hypothesis that if the PAG-RVM pathway is essential for the development of
tolerance, then (1) morphine activation of the PAG-RVM pathway should decline as
tolerance develops, and (2) sex differences in the development of tolerance to morphine
should be reflected as a greater decline in the activation of this pathway in males.
These hypotheses were tested in male and female rats using behavioral testing (hot
plate) and immunohistochemistry to map the activation of the PAG-RVM pathway
following repeated morphine administration (5 mg/kg; s.c.). In males, morphine potency
decreased from 3.0 to 6.3 mg/kg indicating tolerance, and this was paralleled by a
steady decline in the percentage of PAG-RVM output neurons activated by morphine. In
contrast, in females the shift in morphine potency was significantly attenuated (D50 6 to
8.3 mg/kg) and no significant difference in the activity of PAG-RVM output neurons was
noted. These results demonstrate that the greater development of tolerance to
morphine administration in male rats corresponds with a significant reduction in the
activation of the PAG-RVM circuit and suggest a central role for the PAG in the
development of tolerance to morphine.
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4.2 INTRODUCTION
It is estimated that as many as one in five adults currently experience chronic pain. Of
that population, 41% are receiving treatment with opioid-based narcotics (Breivik et al.,
2006). While morphine and other opioid-based narcotics are the most effective
treatment for pain, opiates do not provide adequate pain relief for many people. The sex
of the patient and the development of tolerance to morphine’s analgesic effects are two
particularly important factors that limit the effectiveness of opiates. Men tend to
experience greater analgesia following opiate administration compared to women
(Cepeda & Carr, 2003; Miller & Ernst, 2004), a difference that has been reported for a
wide range of species using both somatic and visceral pain models (Craft, 2003a; Ji et
al., 2006; Loyd & Murphy, 2006; Wang et al., 2006; Loyd et al., 2007).
Recent findings suggest that the midbrain periaqueductal gray (PAG) and its
descending projections to the rostral ventromedial medulla (RVM) contribute to the
sexually dimorphic actions of morphine. Microinjection of morphine directly into the PAG
produces greater antinociception in male compared to female rats (Krzanowska &
Bodnar, 1999; Wang et al., submitted) and blocking PAG opioid receptors reduces
morphine antinociception to a greater extent in female rats (Bernal et al., 2007).
Furthermore, both the anatomy and physiology of the PAG-RVM pathway is sexually
dimorphic, with males having a significantly greater percentage of PAG-RVM neurons
activated by either inflammatory pain (Loyd & Murphy, 2006) or systemic morphine
(Loyd et al., 2007).
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Tolerance is known to occur with repeated or continuous administration of morphine into
the ventrolateral PAG of male rats (Jacquet & Lajtha, 1976; Siuciak & Advokat, 1987;
Tortorici et al., 1999; Tortorici & Morgan, 2002, Tortorici, 1999 #2314; Lane et al., 2005;
Morgan et al., 2006). In addition, blocking opioid binding in the ventrolateral PAG
attenuates tolerance to systemically administered morphine (Lane et al., 2005).
Tolerance appears to be mediated by a reduction in mu opioid receptor signaling
efficacy in PAG neurons (Bagley et al., 2005), an effect that is reversed when mu opioid
receptor coupling is enhanced via upregulated cyclase activity (Hack et al., 2003).
These findings suggest that the PAG contributes to the decrease in antinociception that
occurs with the development of tolerance.
Given that morphine activates a greater percentage of PAG-RVM output neurons in
male compared to female rats (Loyd et al., 2007), our working hypothesis is that if the
PAG-RVM pathway is essential for the development of tolerance to morphine, then (1)
activation of the PAG-RVM pathway should decline as tolerance to repeated injections
of systemic morphine develops, and (2) given that males show greater antinociception
and greater tolerance (Craft et al., 1999; Barrett et al., 2001), these sex differences
should be reflected as a greater decline in the activation of the PAG-RVM pathway in
male compared to female rats. These hypotheses were tested using behavioral
assessment of nociception in combination with immunohistochemistry to map the
activation of the PAG-RVM pathway over the time course of the development of
tolerance to repeated administration of morphine.
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4.2 METHODS
Experimental Subjects
Thirty-five adult male and thirty-seven weight-matched (250-350g) cycling female
Sprague-Dawley rats were used in these experiments (behavior subjects from Harlan,
Indianapolis, IN and anatomy subjects from Zivic-Miller; Pittsburg, PA). Rats were
housed in same-sex pairs on a 12:12 hour light:dark cycle. Access to food and water
was ad libitum throughout the experiment except during surgery and testing. These
studies were performed in compliance with the Institutional Animal Care and Use
Committees at Georgia State University and at Washington State University. All efforts
were made to minimize any possible suffering by the animal, and to reduce the number
of animals used.
Vaginal Cytology
Vaginal lavages were performed daily to confirm that the female rats were cycling
normally and to keep daily records on the stages of their cycle in respect to
experimental testing. Stage of estrous was determined for two weeks prior to testing
and during the three days of morphine or saline injections. Proestrus was identified as
a predominance of nucleated epithelial cells and estrus was identified as a
predominance of cornified epithelial cells. Diestrus 1 was differentiated from Diestrus 2
by the presence of leukocytes. Rats that appeared between phases were noted as
being in the more advanced stage.
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Behavioral Assessment of Tolerance to Repeated Morphine Administration
Thirteen male and fourteen female rats were handled daily for five days prior to initiation
of drug administration. Morphine sulfate (5 mg/kg; s.c., provided by the National Institute
on Drug Abuse, Bethesda, MD) was prepared in a 0.9% saline vehicle and administered
systemically twice a day for three consecutive days to male (n=7) and female (n=7) rats.
The 5 mg/kg dose was chosen based on our previous studies demonstrating this to be
the 50% effective dose (ED50) for systemic morphine in male rats (Morgan et al.,
2006b; Wang et al., 2006; Loyd et al., 2007). Control groups consisting of six male and
seven female rats received daily injections of saline (1 ml/kg, s.c.). Tolerance was
assessed on Day 4 by injecting cumulative doses of morphine every 20 minutes
resulting in quarter log doses of 1.8, 3.2, 5.6, 10.0, and 18.0 mg/kg. Nociception was
assessed using the hot-plate test 15 minutes after each injection by an experimenter
blind to the pretreatment condition. The hot plate test measures the latency to lick the
hindpaw when the rat is placed on a 52.5oC plate. If the animal did not respond within
50 seconds, it was removed from the plate and given a score of 50 seconds. The mean
latency at each dose was calculated for male and female rats pretreated with morphine
or saline.
Behavioral Data Analysis and Presentation
The half-maximal antinociceptive effect (D50; Tallarida, 2000) and 95% confidence
intervals (CI) were calculated from dose-response curves generated using GraphPad
software. The lower limit for calculating D50 values was the mean baseline score, and
the upper limit was the mean hot plate latency following administration of the highest
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morphine dose. Changes in D50 between groups were assessed using ANOVA
(GraphPad).
Anatomical Assessment of Tolerance to Repeated Morphine Administration
Retrograde Tracer Injections
Twenty-two male and twenty-four female rats were deeply anesthetized with
ketamine/xylazine (50 mg/kg / 10mg/kg; s.c.). When a surgical plane of anesthesia was
reached, the animal was placed in a stereotaxic frame with bregma and lambda at the
same dorsal-ventral plane. A glass micropipette (10-20 µM) filled with the retrograde
tracer Fluorogold (FG; 2% soln. w/v in saline; Fluorochrome LLC; Denver, CO) was
lowered into the RVM using the following coordinates (in mm): AP: -2.0 Lambda; ML:
0.0; DV: -8.5). FG was iontophoresed (50/50 duty cycle, 7 seconds on/7 seconds off,
7.5 µA current) into the RVM for 25 minutes to facilitate neuronal uptake. The current
was then turned off and the pipette remained in place for an additional 5 minutes prior to
removal to minimize backflow of the tracer along the pipette track. Following the tracer
injection, wounds were sutured closed, the antibiotic Neosporin was applied to the
wound, and the animal was placed in a clean cage to recover under a heat lamp. Upon
complete recovery from the anesthetic, the rat was returned to its original housing
facility.
Morphine Administration
Ten days following tracer injection, animals were administered morphine or saline for
three consecutive days. Morphine sulfate (5 mg/kg, s.c.) was prepared fresh in a 0.9%
saline vehicle within one hour prior to administration. Animals were divided into two
experimental groups: (1) eight male and eight female rats received one daily injection of
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morphine sulfate for three consecutive days and (2) five male and five female rats
received two daily injections of morphine sulfate for three consecutive days. Injections
were administered between the hours of 10:00A.M. and 4:00P.M. with multiple daily
injections separated by six hours. Two control groups were used: (3) the morphine
naïve group consisted of five male and six female rats injected with saline twice daily for
three consecutive days (no morphine injections) and (4) the acute morphine group
consisted of four male and five female rats injected with saline twice daily for 2.5
consecutive days followed by a final injection of morphine (see Table 4.1).
Perfusion fixation
All animals were given a lethal dose of Nembutal (160 mg/kg; i.p.) one hour following
the last injection of morphine or saline. This time point was chosen based on previous
studies showing that expression of c-fos mRNA peaks within 30-60 minutes after
increased neuronal activity, while the Fos protein is detectable after 60 minutes (Sharp
et al., 1991; Murphy et al., 1995; Rizvi et al., 1996; Zimmer et al., 1997). Additionally,
our previous studies show that Fos is expressed in a strong, consistent pattern in the
PAG one hour following systemic morphine administration (Loyd and Murphy, 2006;
Loyd et al., 2007). The animals were transcardially perfused with 200-250 ml of 0.9%
sodium chloride containing 2% sodium nitrite as a vasodilator to remove blood from the
brain. Immediately following removal of blood, 300 ml of 4% paraformaldehyde in 0.1M
phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused
through the brain as a fixative. A final rinse with 200-250 ml of the sodium
chloride/sodium nitrate solution was perfused through the brain to remove any residual
acrolein. Immediately following perfusion, the brains were carefully removed, placed in a
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30% sucrose solution and stored at 4oC for at least one week prior to sectioning.
Sucrose solutions were changed daily to optimize saturation of sucrose into the tissue.
To section the brain, the dura and pia matter were carefully removed and the brains
were cut into six series of 25 µm coronal sections with a Leica 2000R freezing
microtome and stored free-floating in cryoprotectant-antifreeze solution (Watson et al.,
1986b) at –20oC until immunocytochemical processing.
Immunocytochemistry
A 1:6 series through the rostrocaudal axis of each brain was processed for FG and Fos
immunoreactivity as previously described (Murphy & Hoffman, 2001). Briefly, sections
were rinsed extensively in potassium phosphate-buffered saline (KPBS) to remove
cryoprotectant solution immediately followed by a 20-minute incubation in 1% sodium
borohydride to remove excess aldehydes. The tissue was then incubated in primary
antibody solution rabbit anti-Fos (Oncogene; Cambridge, MA, lot no. 4194; 1:50,000) in
KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours
at 4°C. After rinsing out the primary antibody with KPBS, the tissue was incubated for
one hour in biotinylated goat anti-rabbit IgG (Jackson Immunoresearch; West Grove,
PA, 1:200), rinsed with KPBS, followed by a one hour incubation in avidin-biotin
peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and
sodium acetate (0.175 M; pH 6.5), Fos was visualized as a black reaction product using
nickel sulfate intensified 3,3’-diaminobenzidine solution containing 0.08% hydrogen
peroxide in sodium acetate buffer. After rinsing, sections were placed in primary
antibody solution rabbit anti-FG (Chemicon; Billerica, MA, lot no. 25060005; 1:10,000) in
KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours
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at 4°C. FG was visualized as a brown reaction product using 3,3’-diaminobenzidine
containing 0.08% hydrogen peroxide in Trizma buffer (pH 7.2). After 15-30 minutes,
three rinses in sodium acetate buffer terminated the reaction. Sections were then
mounted out of saline onto gelatin-subbed slides, air-dried overnight, dehydrated in a
series of graded alcohols, cleared in xylene, and cover-slipped using Permount.
Anatomical Data Analysis and Presentation
Data were analyzed across six representative levels through the rostrocaudal axis of the
PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80). As there was no significant effect
of level in all analyses conducted, data are presented as rostral (Bregma -6.72, -7.04, 7.74) versus caudal (Bregma -8.00, -8.30, -8.80) PAG. The number of PAG-RVM output
neurons (FG+), the total number of activated PAG neurons (Fos+), and the number of
activated PAG-RVM output neurons (Fos+FG) were quantified by an experimenter
blinded to the experimental condition. Cell counts were conducted unilaterally as there
are no differences in the number of FG+ cells for the left versus right side of PAG (Loyd
& Murphy, 2006). The tissue was sectioned at 25 µm so that 125 µm separates each
analyzed level of the PAG thus eliminating any possible bias from counting the same
cell twice. Additionally, previous data have shown that there are no sex differences in
total area (mm2) of the PAG between weight-matched male and female SpragueDawley rats (Loyd & Murphy, 2006).
Data are expressed as the mean + standard error of the mean from which percentages
were calculated. As females have a greater number of PAG-RVM output neurons (Loyd
and Murphy, 2006), data are presented as the percentage of Fos that was colocalized in
PAG-RVM output neurons (%Fos in FG+ cells). A three-way analysis of variance
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(ANOVA) was used to test for significant main effects of sex (male, female), PAG level
(Bregma –6.72 through -8.80) and treatment (two experimental groups of morphine
administration and two control groups). A one-way ANOVA was used for post-hoc
analysis to test for significant main effects of treatment and the Fishers PLSD was used
to determine significant interactions between treatment groups when there was a
significant main effect independent of sex. P<.05 was considered significant for all
analyses.
Photomicrographs were generated using a Synsys digital camera attached to a Nikon
Eclipse E800 microscope. Images were captured with IP Spectrum software, adjusted
to figure format by adjusting brightness and contrast levels using Adobe Photoshop 7.0.

4.4 RESULTS
Experiment 1: Behavioral Assessment of Tolerance to Repeated Morphine
Administration
The objective of the present experiment was to compare the development of tolerance
to morphine in male and female rats. Following three days of morphine or saline
injections, administration of cumulative doses of morphine on Day 4 produced a dosedependent increase in hot-plate latency in all groups tested (Figure 4.1). The
antinociceptive potency of morphine was greatest in male rats pretreated with saline on
days 1-3 (D50 = 3.0 mg/kg). In contrast, the D50 for female rats pretreated with saline
was 6.1 mg/kg, a 2.0 fold difference when compared to males. Consistent with the
development of tolerance, male rats pretreated with morphine showed a significant
rightward shift in the morphine dose-response curve compared to male rats pretreated
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with saline ([F(1,74) = 20.04, p<.001]; Figure 4.1A). Specifically, the D50 increased from
3.0 mg/kg (CI = 2.2 – 3.7) to 6.3 mg/kg (CI = 5.1 – 7.6) in rats pretreated with morphine,
a 2.1 fold shift in the D50. Female rats showed significantly less tolerance than male
rats. In females, pretreatment with morphine on days 1-3 resulted in a small rightward
shift [F(1,115) = 5.63; p<.05] in the dose-response curve from 6.1 mg/kg (CI = 5.2 – 7.0)
to 8.0 mg/kg (CI = 6.6 – 9.4; Figure 4.1B), a 1.3 fold increase.
Experiment 2a: Anatomical Assessment of the PAG During Tolerance to Repeated
Morphine Administration
The next series of experiments were conducted to determine if the activation of the
PAG-RVM pathway decreases during the development of tolerance to repeated
systemic morphine administration in male and female rats. Across all groups (Table
4.1), systemic morphine administration induced extensive Fos expression throughout
the rostrocaudal axis of the PAG. Fos was present in both FG+ and non-FG+ PAG
neurons. No significant main effect of sex [F(1,208)= .764, n.s.] or PAG level [F(5,208)=
.0454, n.s.] was noted in the mean number of morphine-induced Fos-positive neurons in
the PAG. However, there was a significant main effect of treatment [F(3,208)= 8.733,
p<.05] and a significant sex-by-treatment interaction [F(3,208)= 10.617, p<.05]. Male
rats treated with saline had significantly less Fos expression compared to all other
treatment groups in the caudal PAG (Figure 4.2, p<.05). In females, administration of
one dose of morphine resulted in significantly less Fos expression in comparison to the
other treatment groups (Figure 4.2, p<.05). Total Fos expression was comparable
between the two repeated morphine administration groups and, in females, as
compared to the morphine naïve group.
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Experiment 2b: Anatomical Assessment of Tolerance to Morphine in the PAG-RVM
Circuit
Figure 4.3 shows an example of a typical iontophoretic injection of retrograde tracer
Fluorogold (FG) into the RVM of a male (top) and female (bottom) rat. All injections
were located on the midline and dorsal to the pyramidal tract, at the level of the caudal
pole of the facial nucleus (lambda –2.0mm). Injections outside of the RVM were not
included for analysis. Injection of FG into the RVM produced dense retrograde labeling
throughout the rostrocaudal axis of the PAG, with females having a significantly greater
amount of labeling compared to males [F(1,208)=59.610, p<.05] (data not shown; Loyd
et al, 2006, Loyd et al., 2007).
Administration of one dose of morphine following three days of saline injections resulted
in extensive Fos expression in PAG-RVM output neurons across all rostrocaudal levels
of the PAG (Figure 4.4). An analysis of the %Fos in FG+ (PAG-RVM output neurons)
cells revealed a significant main effect of sex [F(1,208)= 41.194, p<.05], treatment
[F(3,208)= 43.607, p<.05] and a significant sex by treatment interaction [F(3,208)=
19.440, p<.05]. There was no significant main effect of PAG level [F(5,208)= .1883, n.s.]
indicating that these results were consistent across the rostrocaudal axis of the PAG.
The %Fos in FG+ neurons decreased as a function of morphine treatment in males only
[F(2,71)= 26.546, p<.05]. Overall, the average %Fos in FG+ neurons decreased from
52±5% in males receiving one injection of morphine to 14±6% in males following the
sixth injection of morphine. In females, the %Fos in FG+ cells was low across all
rostrocaudal levels of the PAG and no significant effect of treatment was observed
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[F(2,83)= 1.919, n.s.]. Together, these results parallel our behavioral data indicating
greater tolerance to morphine in male rats.

4.5 DISCUSSION
In the present study, behavioral and neuroanatomical techniques were used to examine
the role of the PAG-RVM circuit in the development of tolerance to systemic morphine in
male and female rats. The results demonstrate that repeated administration of systemic
morphine induces tolerance in male to a much greater extent than in female rats. In
parallel, repeated morphine administration significantly reduces the activation of PAGRVM neurons by morphine in males but not females. The half maximal antinociceptive
effect of a single injection of morphine was two times greater for female compared to
male rats and is consistent with previous research (Cicero et al., 1997; Cook &
Nickerson, 2005; Ji et al., 2006; Wang et al., 2006). This sex difference in morphine
potency is reflected in the greater activation of PAG-RVM output neurons in males
following morphine administration reported here and previously (Loyd et al., 2007). In
addition, the greater tolerance to morphine in male compared to female rats also is
consistent with previous research (Barrett et al., 2001; Bernal et al., 2007). Our data
show that two injections of morphine per day for three consecutive days was sufficient
to reduce morphine potency by 2.1 times in male rats. However, in females, the half
maximal effective dose of morphine only increased from 6.1 to 8.0 mg/kg. Thus, not
only do female rats show less antinociception in response to morphine, but they also
show much less tolerance to morphine.
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Our data indicate that the PAG and its projections to the RVM likely contribute to the
observed behavioral differences between male and female rats. Both the number of
Fos+ neurons in the PAG and the number of Fos+ neurons in the PAG that were
retrogradely labeled from the RVM following a single dose of morphine was greater in
male compared to female rats. Although there was no significant main effect of sex in
the number of Fos+ neurons in the PAG observed following repeated morphine
administration, there was a progressive decrease in the %Fos in FG+ cells following
three or six repeated injections of morphine in male rats. This decrease in activation of
PAG-RVM output neurons in male rats led to a decrease in the %Fos in FG+ cells so
that male rats were comparable to female rats. Moreover, the slight tolerance observed
in females is consistent with a lack of change in the %Fos in FG+ cells following one,
three, or six repeated injections of morphine. These data correspond very closely with
the behavioral data showing that morphine antinociception is greater in male compared
to female rats and tolerance causes a reduction in morphine potency so that tolerant
male rats experience comparable analgesia to less tolerant female rats. These results
demonstrate that the development of tolerance to morphine is associated with a
reduction in the activation of the PAG-RVM circuit in male rats and provide additional
data demonstrating a central role for the PAG in tolerance to morphine.
Tolerance develops with repeated microinjections of morphine directly into the
ventrolateral PAG (Morgan et al., 2006a; Tortorici et al., 1999) and is associated with a
reduction in mu opioid receptor signaling in the PAG (Bagley et al., 2005). Importantly,
blocking opioid binding in the PAG attenuates the development of tolerance to systemic
morphine administration (Lane et al., 2005). While the PAG does not project directly to
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the spinal cord, it projects heavily to the RVM which in turn projects to the spinal cord
(Beitz, 1982b; Beitz et al., 1983). RVM on-cells and off-cells that are normally inhibited
and activated by morphine, respectively, show normal responses to nociceptive reflexes
during the induction of tolerance following repeated intra-PAG administration of
morphine (Lane et al., 2004). Given that tolerance develops to a greater degree when
morphine is administered directly into the PAG compared to administration into the RVM
(Morgan et al., 2005) and that there is a corresponding progressive decrease in the
activation of PAG-RVM neurons, these data together indicate that a key mechanism for
tolerance resides within the PAG.
Previous data have shown that one systemic injection of morphine induces extensive
Fos expression in the PAG that is comparable in male and female rats (Loyd et al.,
2007). Similarly, in the present study, total Fos expression in the PAG following
morphine administration over three days was not sexually dimorphic. However, unlike
our previous study, acute morphine administration following three days of saline
injections in males did not induce significantly greater Fos labeling compared to salinetreated rats and female rats showed a significant decline in Fos labeling. This difference
in Fos induction by morphine in these two studies suggests that the multiple injections
of saline over three days in the present study induce Fos expression that is independent
of morphine. The significant decline in Fos labeling in the PAG following one dose of
morphine in female rats indicates that there is a sexually dimorphic effect of multiple
injections of saline on the type of stimuli inducing activation in the PAG; further studies
are warranted to examine this result.
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Given that Fos expression in the PAG can be induced by a wide range of stimuli
including fear and anxiety (Kim et al., 1993), changes in respiration (Zhang et al.,
1990b; Harper et al., 1996), vocalization (Davis et al., 1993; Zhang et al., 1994), blood
pressure (Carrive, 1991, Murphy, 1995 #1312; Murphy et al., 1995a), and in fight or
flight responses (Bandler et al., 1985; Bandler & Carrive, 1988b; Depaulis et al., 1992),
it is not surprising that repeated daily injections of saline induced Fos in PAG neurons.
In contrast, PAG neurons retrogradely labeled with FG from the RVM were more likely
to express Fos following morphine administration than in saline treated rats. Moreover,
this increase in Fos expression was greater in male compared to female rats. The
greater Fos expression in FG+ cells correlates with the greater morphine
antinociception produced in male compared to female rats. The limited Fos expression
in the PAG-RVM output neurons of female rats is consistent with the low antinociceptive
potency of morphine in these animals. Likewise, the lack of change in Fos expression
with repeated morphine administration is consistent with the limited antinociceptive
tolerance to repeated intra-PAG microinjections of morphine in female rats.
It was recently reported that males have a higher density of mu opioid receptor (MOR)
immunoreactivity in the PAG (Duncan & Murphy, 2005), which may provide a
mechanism for sex differences in the development of tolerance to morphine.
Furthermore, cells that express both MOR and GABA are common in the PAG (Williams
& Beitz, 1990; Kalyuzhny & Wessendorf, 1998) suggesting that morphine directly
modulates the GABAergic neurons that tonically inhibit PAG-RVM neurons (Behbehani
& Fields, 1979; Chieng & Christie, 1994b; Vaughan & Christie, 1997; Commons et al.,
2000b; Tortorici & Morgan, 2002). Administration of GABA agonists hyperpolarizes
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PAG-RVM neurons (Osborne et al., 1996b) and microinjection of GABA antagonists into
the PAG results in a net increase in membrane depolarization, firing frequency,
frequency of EPSPs (Behbehani et al., 1990b) and antinociception (Morgan et al.,
2005). A potential mechanism of action is that morphine is hyperpolarizing GABA
interneurons in the PAG. As tolerance develops, these GABAergic cells are no longer
inhibited by morphine resulting in a progressive increase in tonic inhibition on PAG-RVM
neurons and thus a corresponding decrease in the antinociceptive effects of morphine.
The decrease in Fos expression in PAG neurons projecting to the RVM is consistent
with this model and indicates that tolerance is caused by a change in morphinesensitive GABAergic neurons.
The PAG also contains a high density of estrogen (ERα) receptors (Murphy & Hoffman,
1999; Murphy & Hoffman, 2001; Marson & Murphy, 2006) and approximately 25% of
PAG-RVM neurons contain ERα (Loyd and Murphy, unpublished observations).
Estrogen has been shown to uncouple MOR from G protein-gated inwardly rectifying
potassium channels, thus reducing morphine hyperpolarization of PAG-RVM neurons
(Kelly et al., 2003). In the present study, circulating estrogen acting at ERα receptors
may be uncoupling MOR in the PAG of female rats, resulting in an overall reduction in
the activity of these cells and the analgesic effects. Interestingly, it has been shown that
the excitability of neurons in the PAG is variable across the estrous cycle of the rat,
such that during estrus and late diestrus, GABA receptor antagonists greatly increase
PAG output neuronal firing rates, suggesting a decrease in GABAergic tone (Brack &
Lovick, 2007).
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Cycling females were used in these studies; all rats continued to cycle normally during
the three consecutive days of morphine or saline administration. The activation of PAG
neurons in females tended to be more variable compared to males and stage of estrous
may potentially affect morphine potency and tolerance. Unfortunately, in the present
study we were unable to statistically analyze the effect of cycle on morphine potency
due to limitations in the number of animals per stage of estrous. Upon looking for trends
in the data, there appears to be an effect of cycle on the activation of the PAG following
repeated administration of morphine. Female rats in diestrus 2 had on average two
times more Fos expression in the PAG following six repeated doses of morphine (n=3)
compared to rats in estrus (n=2; data not shown). In addition, rats in diestrus 2 (n=3)
that received three repeated doses of morphine had on average two times more
activated FG+ (%Fos in FG+) cells as compared to rats in estrus (n=2) and in diestrus 1
(n=3; data not shown). No other trends were observed, however, further studies are
clearly warranted to examine the potential effect of estrous cycle on tolerance.

4.6 CHAPTER SUMMARY
In summary, the results of the present study indicate that tolerance to repeated
systemic injections of morphine occurs to a greater extent in male compared to female
rats. As tolerance develops, there is a corresponding steady decline in the activation of
the PAG-RVM pathway in male rats. Activation of this pathway by morphine in female
rats is not significant, and it does not significantly decline following repeated
administration of morphine. Together, these data provide additional data demonstrating
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a central role for the PAG in the development of tolerance to repeated administration of
morphine.
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Table 4.1: Dosing schedule for experimental and control groups
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Figure 4.1. Comparison of tolerance to the antinociceptive effects of morphine in male
(A) and female (B) rats. Rats were pretreated with morphine (5mg/kg) or saline twice a
day for 3 days. Morphine dose-response curves for antinociception on the hot plate
(HP) test were generated on Day 4 using a cumulative dosing paradigm. Both
antinociceptive potency and tolerance to morphine were greater in male compared to
female rats.
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Figure 4.2. Mean number of Fos-positive cells in male and female rats injected with
either morphine (5mg/kg) or saline once or twice daily for three days for the rostral (A;
Bregma

-6.72, -7.04, -7.74) and caudal (B; Bregma -8.00, -8.30, -8.80) PAG. The #

indicates a significant main effect of treatment (morphine and saline) and the * indicates
a significant main effect of sex. Saline: morphine naïve; 1 Dose: saline pretreatment
followed by one dose of morphine; 3 Doses: one dose of morphine per day; 6 Doses:
two doses of morphine per day.
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Figure 4.3. Color photomicrograph of representative examples of FG injection sites at
the RVM of a male (top) and female (bottom) rat. Injection sites were limited to
localization within the bottom third of the medulla along the midline between the facial
nuclei and dorsal to the pyramidal tract. Gi: gigantocellularis; py: pyramidal tract; 4V:
fourth ventricle; 7: facial nucleus.
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Figure 4.4. Percentage of Fos-positive neurons that were retrogradely labeled from the
RVM (%Fos in FG+ cells) in male (solid bars) and female (open bars) rats injected with
either morphine or saline once or twice daily for three days for the rostral (A; Bregma 6.72, -7.04, -7.74) and caudal (B; Bregma -8.00, -8.30, -8.80) PAG. A decrease in
labeling is evident with an increase in the number of morphine injections for male rats.
The # indicates a significant effect of treatment and the * indicates a significant effect of
sex. Saline: morphine naïve; 1 Dose: saline pretreatment followed by one dose of
morphine; 3 Doses: one dose of morphine per day; 6 Doses: two doses of morphine per
day.
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5.1 ABSTRACT
The periaqueductal gray (PAG) is involved in many gonadal steroid-sensitive behaviors,
including responsiveness to pain. The PAG projects to the rostral ventromedial medulla
(RVM), comprising the primary circuit driving pain inhibition. Morphine administered
systemically or directly into the PAG produces greater analgesia in male compared to
female rats, while manipulation of gonadal hormones alters morphine potency in both
sexes. It is unknown if these alterations are due to steroidal actions on PAG neurons
projecting to the RVM. The expression of androgen (AR) and estrogen (ERα) receptors
in the PAG of female rats and within this descending inhibitory pathway in both sexes is
unknown. The present study used immunohistochemical techniques (1) to map the
distribution of AR and ERα across the rostrocaudal axis of the PAG; and (2) to
determine whether AR and/or ERα were colocalized on PAG neurons projecting to the
RVM in male and female rats. AR and ERα immunoreactive neurons (AR-IR, ERα-IR)
were densely distributed within the caudal PAG of male rats, with the majority localized
in the lateral/ventrolateral PAG. Females had significantly fewer AR-IR neurons, while
the quantity of ERα was comparable between the sexes. In both sexes, approximately
25-50% of AR-IR neurons and 20-50% of ERα-IR neurons were retrogradely labeled.
This study provides direct evidence of the expression of steroid receptors in the PAG
and the descending pathway driving pain inhibition in both male and female rats and
may provide a mechanism whereby gonadal steroids modulate pain and morphine
potency.

99

5.2 INTRODUCTION
Anatomical and physiological studies have shown that the midbrain periaqueductal gray
(PAG) plays a modulatory role in a variety of behaviors including antinociception
(Reynolds, 1969; Behbehani & Fields, 1979; Heinricher et al., 1987; Behbehani, 1995;
Budai et al., 1998), reproduction (McCarthy et al., 1991b; Ogawa et al., 1991; Murphy &
Hoffman, 1998; Daniels et al., 1999), fear and anxiety (Kim et al., 1993), aggression
(Bandler et al., 1985; Bandler & Carrive, 1988b; Depaulis et al., 1992; Scordalakes &
Rissman, 2004) and vocalization (Davis et al., 1993; Zhang et al., 1994). While these
behaviors have been shown to be modulated by gonadal steroids, our knowledge of the
qualitative and quantitative aspects of gonadal steroid receptors in the PAG is
incomplete. The PAG has been shown to contain a large number of both androgen
receptor (AR) and estrogen receptor (ERα) immunoreactive neurons (Murphy &
Hoffman, 1999; Murphy & Hoffman, 2001), however these studies were conducted
exclusively in male rats. While the distribution of ERα in the female PAG has been
reported in a few species, including the cat (VanderHorst et al., 1998), the golden
hamster (Boers et al., 1999), the guinea pig (Turcotte & Blaustein, 1993) and the rhesus
monkey (Vanderhorst et al., 2002; VanderHorst et al., 2004), the quantity and
distribution of AR and ERα in the female rat is currently unknown.
The PAG projects heavily to the rostral ventromedial medulla (RVM), which in turn
projects to the dorsal horn of the spinal cord. This PAG-RVM-spinal cord circuit is the
primary neural pathway that elicits the antinociceptive effects of opiates. Previous
studies have reported sex differences in the anatomical organization of the projections
from the PAG to the RVM and activation of these neurons by inflammatory pain (Loyd &
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Murphy, 2006). In addition, there are significant sex differences in the activation of this
pathway by systemic morphine, both in the presence and absence of inflammatory pain
(Loyd & Murphy, 2006; Loyd et al., 2007; Loyd et al., 2008). To date, it is not known
whether ERα and AR are expressed on PAG neurons projecting to the RVM. Numerous
behavioral studies have shown that sex differences in opioid analgesia are modulated
by both the organizational and activational effects of gonadal steroids (Kepler et al.,
1989; Islam et al., 1993; Krzanowska & Bodnar, 1999; 2000; Stoffel et al., 2003;
Cataldo et al., 2005; Stoffel et al., 2005). Male rats castrated at birth experience
decreased morphine potency in adulthood, while female rats masculinized at birth
experience greater morphine potency in adulthood whether morphine is administered
systemically (Cicero et al., 2002) or directly into the PAG (Krzanowska et al., 2002).
Similarly, both systemic and central administration of morphine is less effective in
gonadectomized adult males and more effective in ovariectomized adult females
(Kepler et al., 1989; Ratka & Simpkins, 1991; Krzanowska & Bodnar, 1999; Terner et
al., 2002; Stoffel et al., 2003; Stoffel et al., 2005; Terner et al., 2005); effects are
reversed with hormone replacement (Ratka & Simpkins, 1991; Kiefel & Bodnar, 1992);
Stoffel et al., 2003; (Ji et al., 2007).
While the organizational and activational effects of gonadal steroids are likely to
contribute to the sexually dimorphic actions of morphine, it is currently unknown whether
gonadal steroid receptors are expressed on PAG neurons projecting to the RVM. In
addition, the qualitative and quantitative aspects of AR and ERα expression in the PAG
of the female rat are not known. The present studies utilized immunohistochemistry to
map (1) the quantity and distribution of AR and ERα immunoreactive neurons across

101

the rostrocaudal axis of the PAG; and (2) to determine if the PAG neurons projecting to
the RVM express AR and ERα immunoreactivity. Due to a lack of commercially
available antibodies at the time these studies were conducted, ERβ was not analyzed in
this study. This study is the first to report AR and ERα immunoreactivity in the PAG and
its descending projections to the RVM in both male and female rats.

5.3 METHODS
Subjects
Six adult male and six weight-matched (250-350g) cycling female Sprague-Dawley rats
were used in these experiments (Zivic-Miller; Pittsburgh, PA). Rats were housed in
same-sex pairs on a 12:12 hour light:dark cycle. Access to food and water was ad
libitum throughout the experiment except during surgery. These studies were performed
in compliance with the Institutional Animal Care and Use Committee at Georgia State
University. All efforts were made to reduce the number of animals used in these
experiments and to minimize any possible suffering by the animal.
Vaginal Cytology
Vaginal lavages were performed daily beginning two weeks prior to experimental
manipulations to confirm that the female rats were cycling normally and to keep daily
records on the stages of their cycle up to the day of sacrifice. Proestrus was identified
as a predominance of nucleated epithelial cells and estrus was identified as a
predominance of cornified epithelial cells. Diestrus 1 was differentiated from Diestrus 2
by the presence of leukocytes. Rats that appeared between phases were noted as
being in the more advanced stage.
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Retrograde Tracer Injections
Animals were deeply anesthetized with a cocktail of ketamine/xylazine/acepromazine
(50 mg/kg / 3.3 mg/kg / 3.3 mg/kg; i.p.; Henry Schein, Melville, NY). When a surgical
plane of anesthesia was reached each animal was placed in a stereotaxic frame and
the skull was adjusted so bregma and lambda were at the same dorsal-ventral plane.
Glass micropipettes (10-20 µM) filled with the retrograde tracer Fluorogold (FG; 2%
soln. w/v in saline; Fluorochrome LLC; Denver, CO) were lowered into the RVM using
the following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0; DV: -8.5). FG was
iontophoresed (50/50 duty cycle, 7.5 µA current) into the RVM for 25 minutes to
facilitate neuronal uptake. The current was then turned off and the pipettes remained in
place for an additional 5 minutes prior to removal to minimize backflow of the tracer
along the pipette track. Following tracer injections, wounds were sutured closed, the
antibiotic Neosporin was applied to the wound, and the animals were placed in clean
cages to recover under a heat lamp. Upon complete recovery from the anesthetic,
animals were returned to their original housing facilities.
Perfusion fixation
Ten days following surgery, animals were given a lethal dose of Nembutal (160 mg/kg;
i.p.) and transcardially perfused with 200-250 ml of 0.9% sodium chloride containing 2%
sodium nitrite as a vasodilator to remove blood from the brain. Immediately following
removal of blood, 300 ml of 4% paraformaldehyde in 0.1M phosphate buffer containing
2.5% acrolein (Polyscience; Niles, IL) was perfused through the brain as a fixative. A
final rinse with 200-250 ml of the sodium chloride/sodium nitrate solution was perfused
through the brain to remove any residual acrolein. Immediately following perfusion, the
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brains were carefully removed, placed in a 30% sucrose solution and stored at 4°C for
at least one week prior to sectioning. Sucrose solutions were changed daily to optimize
saturation of sucrose into the tissue. To section the brain, the dura and pia mater were
carefully removed and the brains were cut into six series of 25 µm coronal sections with
a Leica 2000R freezing microtome and stored free-floating in cryoprotectant-antifreeze
solution (Watson et al., 1986b) at –20oC until immunocytochemical processing. The
tissue was sectioned at 25 µm so that 125 µm separates each analyzed level of the
PAG thus eliminating any possible bias from counting the same cell twice during data
collection.
Immunocytochemistry
A 1:6 series through the rostrocaudal axis of each brain was processed for FG
immunoreactivity and AR (n=5 males; n=6 females) or ERα (n=6 males; n=5 females)
immunoreactivity as previously described (Murphy & Hoffman, 2001). Briefly, sections
were rinsed extensively in potassium phosphate-buffered saline (KPBS) to remove
cryoprotectant solution, immediately followed by a 20-minute incubation in 1% sodium
borohydride to remove excess aldehydes. The tissue was then incubated in either
primary antibody solution rabbit anti-AR (Santa Cruz Biotechnology; Santa Cruz, CA, lot
no. L0407; 1:10,000) or rabbit anti-ERα (Santa Cruz Biotechnology; Santa Cruz, CA, lot
no. I2607; 1:20,000) in KPBS containing 1.0% Triton-X for one hour at room
temperature followed by 48 hours at 4°C. The rabbit anti-AR antiserum was prepared
against a peptide mapping at the N-terminus of AR of human origin
(MEVQLGLGRVYPRPPSKTYRG) corresponding to amino acids 2-21 (manufacturer’s
technical information) and specificity has been confirmed (Creutz & Kritzer, 2004). The
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rabbit anti-ERα antiserum was prepared against a peptide mapping at the C-terminus of
ERα of mouse origin (HSLQTYYIPPEAEGFPNTI) corresponding to amino acids 580559 (manufacturer’s technical information) and specificity has been confirmed (Quesada
et al., 2007).
After rinsing out the primary antibody with KPBS, the tissue was incubated for one hour
in biotinylated goat anti-rabbit IgG (Jackson Immunoresearch; West Grove, PA, 1:600),
rinsed with KPBS, followed by a one hour incubation in an avidin-biotin peroxidase
complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and sodium acetate
(0.175 M; pH 6.5), AR or ERα immunoreactivity was visualized as a black reaction
product using nickel sulfate intensified 3,3’-diaminobenzidine solution containing 0.08%
hydrogen peroxide in sodium acetate buffer. After rinsing, AR or ERα labeled sections
were then placed in primary antibody solution rabbit anti-FG (Chemicon; Billerica, MA,
lot no. 25060005; 1:10,000) in KPBS containing 1.0% Triton-X for one hour at room
temperature followed by 48 hours at 4°C. FG was visualized as a brown reaction
product using 3,3’-diaminobenzidine containing 0.08% hydrogen peroxide in Trizma
buffer (pH 7.2). After 15-30 minutes, three rinses in sodium acetate buffer terminated
the reaction and tissue was given a final rinse in KPBS. Sections were then mounted
out of saline onto gelatin-subbed slides, air-dried and dehydrated in a series of graded
alcohols. Tissue-mounted slides were then cleared in xylene and glass cover-slipped
using Permount.
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Data Analysis and Presentation
Data were analyzed across six representative levels through the rostrocaudal axis of the
PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80). The number of AR
immunoreactive neurons (AR-IR), ERα immunoreactive neurons (ERα-IR), and the
number of AR-IR and ERα-IR neurons that were retrogradely labeled (AR/FG+,
ERα/FG+) were quantified. The experimenter was blind to the experimental condition. In
levels where significant differences were found, a second blinded observer confirmed
results. Cell counts were conducted unilaterally as there are no differences in the
number of FG+ cells (Loyd & Murphy, 2006) or the number of AR-IR and ERα-IR
neurons (Murphy & Hoffman, 2001) for the left versus right side of PAG. Additionally,
previous data have shown that there are no sex differences in total area (mm2) of the
PAG between weight-matched male and female Sprague-Dawley rats (Loyd & Murphy,
2006).
Data are reported as the mean + standard error of the mean (SEM) from which
percentages were calculated and reported as the percentage of receptor that was
localized in retrogradely labeled cells (%AR/FG+; %ERα/FG+) or as the percentage of
retrogradely labeled cells that were colocalized with receptor (%FG/AR; %FG/ ERα). A
three-way analysis of variance (ANOVA) was used to test for significant main effects of
sex (male, female), PAG level (Bregma –6.72 through -8.80), and PAG subdivision
(dorsomedial, lateral/ventrolateral). For percentile date, percentages were transformed
to standard scores. Fishers’s post hoc tests were used to determine specific group
differences when a main effect or interaction was observed. P<.05 was considered
significant for all analyses. For data presentation, a representative animal from each
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experimental group was selected and the distribution of (1) AR-IR neurons, (2) ERα-IR
neurons, (3) FG+ neurons, (4) AR/FG+ neurons and (5) ERα/FG+ neurons within the
PAG were plotted using a Nikon Drawing Tube attached to a Nikon Optiphot
microscope. Plots were then scanned onto the computer and adjusted to figure format
using Adobe Illustrator 10. Photomicrographs were generated using a Synsys digital
camera attached to a Nikon Eclipse E800 microscope. Images were captured with IP
Spectrum software and adjusted to figure format by alterations in brightness and
contrast levels using Adobe Photoshop 7.0.

5.4 RESULTS
Androgen Receptor Distribution in the PAG
AR-IR neurons were distributed across the rostrocaudal axis of the PAG in both male
and female rats (Figure 5.1; green circles). AR-IR neurons were confined to the
dorsomedial and lateral/ventrolateral subdivisions of the PAG, with the dorsolateral
subdivision of the PAG lacking AR-IR neurons. These results are consistent with
previous studies showing AR localization in the PAG of male rats (Murphy & Hoffman,
1999; Murphy & Hoffman, 2001). While the qualitative distribution of AR-IR neurons was
similar in both males and females, quantitatively males had a significantly greater
number of AR-IR neurons compared to females [F(1, 54)=22.7, p<.00001) (Figure 5.2;
green bars) with a significantly greater number of AR-IR neurons localized in the
lateral/ventrolateral PAG compared to the dorsomedial subdivision [F(1, 108)=22.1,
p<.0001]. This sex difference was evident across the rostrocaudal axis of the PAG.
There was no main effect of level of PAG [F(5,54)=1.2; n.s.] and no significant sex by
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level interaction [F(5,54)=0.3; n.s.], indicating that the number of AR-IR neurons
remained consistent across the rostrocaudal axis of the PAG of both male and female
rats.
Estrogen (α) Receptor Distribution in the PAG
ERα-IR neurons were densely distributed throughout the rostrocaudal axis of the PAG
in both male and female rats (Figure 5.1; purple circles). Similar to the distribution of
AR-IR neurons, ERα-IR neurons were confined to the dorsomedial and
lateral/ventrolateral subdivisions of the PAG, with the majority of ERα-IR neurons
localized in the lateral/ventrolateral PAG [F(1, 108)=105.8, p<.0001]. Overall, there was
no sex difference in the number of ERα-IR neurons in the PAG [F(1, 54)=1.2, n.s.]
(Figure 5.2; purple bars). A significant increase in the number of ERα-IR neurons [F(5,
54)=9.02, p<.0001] was noted along the rostrocaudal axis of the PAG. All female rats
were cycling normally during these experiments.
Androgen Receptor Distribution in PAG Neurons Projecting to the RVM
All iontophoretic injections of the retrograde tracer Fluorogold (FG) into the RVM were
located on the midline and dorsal to the pyramidal tract, at the level of the caudal pole of
the facial nucleus (lambda –2.0mm). Analysis was limited to injection sites that occurred
between the facial nucleus and the olivary complex across approximately 2mm
rostrocaudally (Bregma -9.30 to -11.60). In our studies using anterograde tracing from
the PAG to the RVM, we have noted that this region of RVM contains the highest
density of anterogradely labeled fibers and is remarkably consistent throughout this
2mm window of RVM (unpublished observations). Injections outside of the RVM were
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not included for analysis. Only male and female rats with comparable injection sites
were used for analysis. Injection of FG into the RVM produced dense retrograde
labeling throughout the rostrocaudal axis of the PAG consistent with our previous
studies (Loyd et al, 2006, Loyd et al., 2007; Loyd et al., 2008). Females had a
significantly greater number of PAG cells retrogradely labeled from the RVM compared
to males [F(1,70)=14.4, p<.0003].
Figure 5.3 shows an example of AR and FG immunoreactivity within the lateral PAG of
a representative male (A-B) and female (C-D) rat. AR-IR neurons there were
retrogradely labeled were densely localized throughout the rostrocaudal axis of the PAG
in both male and female rats (Figure 5.4; green stars), with males expressing more dual
labeled cells [F(1,54)=19.5; p<.0001]. The percentage of retrogradely labeled cells that
expressed AR was comparable between the sexes [F(1,54)=13.51; n.s.] (Figure 5.5,
%FG/AR), and significantly increased moving caudally through the PAG [F(5,54)=7.29;
p<.0001]. Since female rats had a greater number of PAG neurons projecting to the
RVM compared to males, the percentage of AR that was localized in retrogradely
labeled cells was also determined (Figure 5.5; %AR/FG+) and was found to be
comparable between the sexes [F(1, 54)=1.4; n.s.].
Estrogen (α) Receptor Distribution in PAG Neurons Projecting to the RVM
An example of ERα and FG immunoreactivity within the lateral PAG of a representative
male (A-B) and female (C-D) rat is shown in Figure 5.6. ERα-IR neurons that were
retrogradely labeled were densely localized throughout the rostrocaudal axis of the PAG
in both male and female rats (Figure 5.4; purple stars) [F(1,54)=1.1; n.s.], with the
majority localized in the lateral/ventrolateral subdivision [F(1, 54)=7.5; p<.0001]. Across
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all levels and regions of the PAG, the percentage of retrogradely labeled cells that
expressed ERα was comparable between the sexes [F(1,54)=0.176; n.s.] (Figure 5,
%FG/ERα). Similarly, the percentage of ERα that was localized in retrogradely labeled
cells was comparable between the sexes [F(1, 54)=0.292; n.s.] (Figure 5.5;
%ERα/FG+). Additionally, a significantly greater percentage of retrogradely labeled cells
that expressed ERα were observed in the caudal PAG [F(5,54)=15.1; p<.0001].

5.5 DISCUSSION
The PAG has been implicated in a variety of hormone-sensitive behaviors (Bandler &
Shipley, 1994b; Keay & Bandler, 2001; 2002); however, gonadal steroid receptor
expression in the PAG had not been reported in both male and female rats. Here we
report that the expression of AR is sexually dimorphic along the entire rostrocaudal axis
of the PAG, with males having a significantly greater number of immunoreactive
neurons. No sex differences were noted in the qualitative or quantitative aspects of ERα
expression in the PAG. In the present study, ERβ was not examined due to a lack of a
reliable antibody at the time these studies were conducted; therefore, the possibility
remains that the expression of ERβ in the PAG is sexually dimorphic. Similarly, in this
study we were unable to determine the effects of estrous on ERα expression in the PAG
due to low number of animals. On the day of sacrifice, ten days following tracer
injections, all female rats were in either the estrus (n=4) or proestrus (n=2) phase of
their cycle; no animals were in the diestrus phase.
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The sex difference in the expression of AR in the PAG may play a role in sex
differences in pain and analgesia. There are numerous behavioral studies indicating a
role of gonadal steroids in modulating morphine potency. Gonadectomy reduces
morphine potency in male rats (Kepler et al., 1989) and increases morphine potency in
females (Terner et al., 2002; Terner et al., 2005), while hormone replacement reverses
these effects (Stoffel et al., 2003; Stoffel et al., 2005). Masculinizing female rat pups
with testosterone increases morphine potency to male-like levels (Cicero et al., 2002).
In addition, testosterone has been shown to oppose the effects of estradiol on neuronal
excitability (Edwards et al., 1999) and decrease pain sensitivity in both male and female
rats (Aloisi et al., 2004). A greater expression of AR in the PAG of males may provide
an anatomical substrate for the sexually dimorphic modulation of pain by gonadal
steroids.
The distribution of AR-IR and ERα-IR neurons was remarkably similar; both receptor
types were preferentially localized within the dorsomedial and lateral/ventrolateral
subdivisions of the PAG and both increased in density along the rostrocaudal axis of the
PAG. These results are similar to the distribution of AR-IR and ERα-IR neurons
previously reported in the PAG of the male rat (Murphy & Hoffman, 1999; Murphy &
Hoffman, 2001). In addition, the distribution of ERα-IR neurons in the female rat PAG is
similar to that previously reported in the cat (VanderHorst et al., 1998), the golden
hamster (Boers et al., 1999), the guinea pig (Turcotte & Blaustein, 1993) and the rhesus
monkey (Vanderhorst et al., 2002; VanderHorst et al., 2004).
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Steroid Receptor Colocalization within the Endogenous Descending Pathway Driving
Pain Inhibition
The dense projections from the PAG to the RVM provide an essential neural circuit for
the antinociceptive effects of opiates. Many behavioral studies have reported an effect
of steroid hormones on morphine potency; however, this study is the first to report the
expression of AR and ERα within the endogenous descending pathway driving pain
inhibition. Using immunohistochemical analysis, we report that AR and ERα were
expressed on PAG neurons projecting to the RVM in both the dorsomedial and
lateral/ventrolateral subdivisions of the PAG. Male rats had a greater number AR-IR
neurons that were retrogradely labeled, however, there was so sex difference in either
the percentage of retrogradely labeled cells that expressed AR or the percentage of AR
that was located within retrogradely labeled cells. Similarly, the percentage of ERα that
was localized in retrogradely labeled cells was comparable between the sexes and was
significantly greater in the caudal PAG with the majority localized in the
lateral/ventrolateral subdivision.
Role in Pain and Analgesia
The present results report a dense colocalization of gonadal steroid receptors on PAG
neurons projecting to the RVM, which may provide the anatomical substrate for the
reported sex differences in morphine potency. Between 27-50% of PAG neurons
projecting to the RVM contain mu opioid receptor (MOR); these MOR+ cells are
localized primarily within the caudal lateral/ventrolateral PAG (Commons et al., 2000b;
Wang & Wessendorf, 2002), in the same subdivision of the PAG that we report a dense
distribution of both steroid hormone receptors. Estradiol has been shown to both
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uncouple MORs from G protein-gated inwardly rectifying potassium channels causing a
reduction in hyperpolarization by MOR agonists (Kelly et al., 2003) and induce mu
opioid receptor (MOR) internalization (Eckersell et al., 1998b). Furthermore, MOR
internalization requires the presence of ERα (Micevych et al., 2003) suggesting that
colocalization of MOR and ERα in the descending inhibitory circuit may provide a
mechanism through which gonadal hormones differentially affect morphine potency in
male and female rats.
Although not determined in the present study, it is possible that both AR and ERα are
colocalized within the same PAG cells, as is the case in other brain areas (Wood &
Newman, 1995); (Greco et al., 1998). A population of neurons expressing both AR and
ERα in the PAG may provide a potential mechanism for the diverse effects of gonadal
steroid hormones. For example, there are numerous reports of sex differences in pain
sensitivity; however, there is no clear consensus on the direction of the sex difference
(Mogil et al., 2000; Gaumond et al., 2002; Aloisi et al., 2004; LaCroix-Fralish et al.,
2005). In addition, pain sensitivity varies across the rat estrous cycle (Gintzler, 1980)
and the human menstrual cycle (Cogan & Spinnato, 1986; Hellstrom & Anderberg,
2003). Sex differences in circulating gonadal steroids acting via a differential expression
of AR and ERα within the same PAG neuron may provide a mechanism for the diverse
effects of gonadal steroids on pain sensitivity.
Other Functional Considerations
The PAG has also been implicated in the regulation of the autonomic system controlling
blood pressure, heart rate, and regional blood flow, all of which have shown to be
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modulated by gonadal hormones (Alper & Schmitz, 1996); (Morgan & Pfaff, 2001). In
parallel, the PAG initiates defensive and aggressive behaviors, such as the ‘fight or
flight’ response (Bandler et al., 1985; Bandler & Carrive, 1988b; Depaulis et al., 1992;
Scordalakes & Rissman, 2004), and evidence suggests that gonadal hormones
increase these behaviors in both male and female rats (Albert et al., 1990; Albert et al.,
1991; Johansson et al., 2000). Additionally, the PAG has also been implicated in
initiating sex behavior, in that stimulation of the PAG facilitates lordosis in female rats
(Sakuma & Pfaff, 1979a; 1979b; McCarthy et al., 1991b), while lesions of the PAG
suppress this behavior (Sakuma & Pfaff, 1979b; Lonstein & Stern, 1998). Here we
report that the PAG, an anatomical substrate essential for the integration of sensory
input and autonomic output, contains a large population of gonadal steroid receptorexpressing neurons, which appear to be involved in modulating both autonomic and
sensory responses involved in producing steroid-sensitive behaviors.

5.6 CHAPTER SUMMARY
The present study demonstrates that there are sex differences in the qualitative and
quantitative aspects of the gonadal steroid receptors in the PAG. These reported
differences in AR and ERα immunoreactivity in the PAG have an important impact on
steroid-sensitive behaviors modulated by the PAG, such as reproduction, aggression,
autonomic regulation, pain and morphine analgesia. We additionally report that the
primary neural circuit for the antinociceptive effects of opioids expresses steroid
receptors and may provide a direct mechanism for sex differences in morphine
analgesia.
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Figure 5.1. Distribution of cells in the PAG immunoreactive for AR (green circles) and
ERα (purple circles) in male (left side of plots) and female rats (right side of plots) at six
rostrocaudal levels (A-F) of the PAG.
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Figure 5.2. Bar graphs display the mean number (+ S.E.M.) of AR immunoreactive cells
(green bars) and ERα immunoreactive cells (purple bars) across six rostrocaudal levels
of the PAG. Cell counts were combined for the dorsomedial and lateral/ventrolateral
subdivisions of PAG. # denotes a significant sex difference in mean number of steroid
receptors.
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Figure 5.3. Color photomicrograph showing a low (A,C) and high (B,D) power example
of single- and double-labeled AR and FG immunoreactive cells in the lateral PAG
(bregma -8.00) of a male (A-B) and female rat (C-D). Scale bar = 100 µm for low power
images; scale bar = 50 µm for high power images.
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Figure 5.4. Distribution of cells in the PAG retrogradely labeled from the rostral
ventromedial medulla (black circles) and immunoreactive for AR (green stars) and ERα
(purple stars) in male (left side of plots) and female rats (right side of plots) at six
rostrocaudal levels of the PAG.
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Figure 5.5. Bar graphs display the mean (+ S.E.M.) %AR/FG+, %FG/AR+, %ERα/FG+,
and %FG/ERα+ immunoreactive neurons for the dorsomedial combined with
lateral/ventrolateral regions of PAG across six rostrocaudal levels of the PAG. #
denotes a significant sex difference in %FG/AR+ by level.
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Figure 5.6. Color photomicrograph showing a low (A,C) and high (B,D) power example
of single- and double-labeled ERα and FG immunoreactive cells in the lateral PAG
(bregma -8.00) of a male (A-B) and female rat (C-D). Scale bar = 100 µm for low power
images; scale bar = 50 µm for high power images.
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6.1 ABSTRACT
Opioid-based narcotics are the most widely prescribed therapeutic agents for the
alleviation of persistent pain; however, it is becoming increasingly clear that morphine is
less potent in women compared to men. Morphine primarily binds to mu opioid
receptors (MOR), and the periaqueductal gray (PAG) contains a dense population of
MOR-expressing neurons. Via its descending projections to the rostral ventromedial
medulla and then the dorsal horn of the spinal cord, the PAG is considered an essential
neural substrate for opioid-based analgesia. We hypothesized that MOR expression in
the PAG is sexually dimorphic, and that this receptor expression is both necessary and
sufficient for eliciting sex differences in morphine potency. Using immunohistochemistry,
we report that males have a significantly higher expression of MOR in the ventrolateral
PAG (vlPAG) compared to cycling females, while the lowest level of expression are
observed during proestrus. Microinjection of morphine directly into the vlPAG produced
a significantly greater degree of antihyperalgesia to a thermal stimulus during CFAinduced inflammatory pain in males compared to proestrus and estrus females.
Selective lesions of MOR-expressing neurons in the vlPAG resulted in a significant
reduction in morphine antihyperalgesia in males only, and this reduction was positively
correlated with the level of vlPAG MOR expression. Together, these results indicate that
MOR-expressing neurons in the vlPAG are sexually dimorphic. Furthermore, these
neurons are both necessary and sufficient for eliciting sexually dimorphic
antihyperalgesia following systemic morphine administration, providing a potential
primary mechanism for sex differences in morphine potency.
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6.2 INTRODUCTION
In both humans and rodents, morphine produces a significantly greater degree of
analgesia in males compared to females (Cepeda et al., 2002; Cepeda & Carr, 2003;
Miller & Ernst, 2004). Sex differences in morphine analgesia have been demonstrated in
studies employing either acute or persistent orofacial (Okamoto et al., 2005), visceral (Ji
et al., 2006; 2007) and somatic (Bartok & Craft, 1997; Cicero et al., 1997; Boyer et al.,
1998; Kest et al., 1999; Barrett et al., 2001; Cook & Nickerson, 2005; Wang et al., 2006)
pain models, with ED50 values two times higher in females compared to males (Wang et
al., 2006; Ji et al., 2007). Importantly, sex-based differences in opiate sensitivity are not
due to the pharmacokinetics of morphine as no sex difference has been reported in
serum or brain levels of morphine; and elimination and metabolic rates are comparable
between sexes (Cicero et al., 1996b; Craft et al., 1996; Cicero et al., 1997; Sarton et al.,
2000). Rather, sex related differences in morphine analgesia are likely due to
dissimilarities in opiate receptor density, binding and localization, as well as sex
differences in the anatomy and physiology of opiate-responsive neural circuits (Loyd &
Murphy, 2006; Loyd et al., 2007; Loyd et al., 2008).
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral
ventromedial medulla (RVM), constitutes an essential neural circuit for opioid-based
antinociception (Basbaum et al., 1976; 1978; Fields & Basbaum, 1978; Basbaum &
Fields, 1979; Behbehani & Fields, 1979; Shah & Dostrovsky, 1980; Abols & Basbaum,
1981; Beitz, 1985; Beitz & Shepard, 1985). Administration of mu opioid receptor (MOR)
agonists into the PAG produces potent analgesia that is blocked by central or systemic
administration of the opioid antagonist naloxone (Satoh et al., 1983; Jensen & Yaksh,
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1986; Bodnar et al., 1988b). Similarly, direct administration of MOR antagonists into the
PAG blocks the antinociceptive effects of systemic morphine (Wilcox et al., 1979; Ma &
Han, 1991; Zhang et al., 1998) indicating that the PAG is an essential loci for
exogenous opioid-mediated analgesia.
The ventrolateral PAG (vlPAG) contains a high density of MOR (Mansour et al., 1986;
Mansour et al., 1987; Kalyuzhny et al., 1996; Gutstein et al., 1998; Commons et al.,
1999; Commons et al., 2000b; Wang & Wessendorf, 2002) and approximately 27-50%
of PAG neurons projecting to the RVM express MOR (Commons et al., 2000b; Wang &
Wessendorf, 2002). Unfortunately, previous studies examining the distribution of MOR
within the PAG-RVM circuit were conducted exclusively in males. One mechanism that
may contribute to sex-based differences in morphine potency are sex differences in
MOR expression in the vlPAG. The present studies tested the hypothesis that sex
differences in MOR expression within the vlPAG provide a primary mechanism
underlying the sexually dimorphic effects of morphine across three experimental
designs: (1) immunocytochemical localization of MOR in the vlPAG; (2) microinjection of
morphine directly into the vlPAG and (3) site-specific lesions of MOR-expressing
neuronal populations in the vlPAG.
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6.3 METHODS
Experimental Subjects
Adult weight-matched (250-350g) intact male and cycling female Sprague-Dawley rats
were used in these experiments (Zivic-Miller; Pittsburg, PA). Rats were housed in samesex pairs on a 12:12 hour light:dark cycle. Access to food and water was ad libitum
throughout the experiment except during surgery. These studies were performed in
compliance with the Institutional Animal Care and Use Committee at Georgia State
University. All efforts were made to reduce the number of animals used in these
experiments and to minimize any possible suffering by the animal.
Vaginal Cytology
Vaginal lavages were performed daily beginning two weeks prior to testing to confirm
that all female rats were cycling normally and to keep daily records on the stages of
their cycle in respect to experimental testing. Proestrus was identified as a
predominance of nucleated epithelial cells and estrus was identified as a predominance
of cornified epithelial cells. Diestrus 1 was differentiated from Diestrus 2 by the
presence of leukocytes. However, as there were no significant differences noted in
either the anatomy or behavior of diestrus 1 and diestrus 2 animals, these data are
pooled (diestrus). Rats that appeared between phases were noted as being in the more
advanced stage.
Intra-PAG Cannulae Implantation
Intact males (n=30) and cycling females (n=34) were deeply anesthetized with a cocktail
of ketamine/xylazine/acepromazine (50 mg/kg / 3.3mg/kg / 3.3 mg.kg; i.p.; Henry Shein,

126

Melville, NY). Guide cannulae (22 gauge; 5.0 mm; Plastics One, Roanoke, VA) were
lowered bilaterally into the ventrolateral PAG using the following coordinates (in mm):
AP: +0.75 Lambda; ML: 0.60; DV: -3.5. Cannula skull screws and dental acrylic were
applied to secure placement. Cannulae were flushed daily with 0.5 µl saline over a 60
second period to acclimate the animals to the injection procedure and maintain cannula
patency.
Lesions of Mu Opioid Receptor-Expressing PAG Neurons
Intact males (n=11) and cycling females (n=11) were deeply anesthetized with a cocktail
of ketamine/xylazine/acepromazine (50 mg/kg / 3.3mg/kg / 3.3 mg.kg; i.p.; Henry Shein,
Melville, NY). Dermorphin-saporin (DermSAP; MOR agonist-saporin cytotoxin
conjugate; Advanced Targeting Systems, San Diego, CA) or blank-saporin (BlankSAP;
nonsense peptide-saporin cytotoxin control conjugate; Advanced Targeting Systems,
San Diego, CA) were freshly diluted from stock (DermSap 0.91µg/µl, 46.9µM; BlankSAP
1.5µg/µl, 46.9µM; 32kDa) and stored on ice during experimental procedures. DermSAP
(n=6 males; n=6 females) or BlankSAP (n=5 males; n=5 females) was injected into the
ventrolateral PAG (coordinates in mm): AP: +0.75 Lambda; ML: 0.60; DV: -3.5) using a
1µl Hamilton syringe. DermSAP (3 pmol/400nl; 7.5µM) or BlankSAP (3pmol/400nl;
7.5µM) was microinjected over 30 seconds. This procedure was repeated on the
contralateral side. Saporin has been previously shown to have no effect in the absence
of conjugation (Porreca et al., 2001; Burgess et al., 2002; Vera-Portocarrero et al.,
2006b). In addition, dermorphin has been shown to have a high binding affinity selective
for the MOR (Ki value of 0.7mM) and that conjugation to saporin does not significantly
alter its binding affinity (Ki value of 0.1nM; Porreca et al., 2001). This technique has

127

been previously been shown to result in a significant attenuation of MOR expression in
the RVM (Porreca et al., 2001) and the spinal cord (Kline & Wiley, 2008). Loss of mu
opioid receptor containing neurons was confirmed in the present study using both
immunohistochemistry and autoradiography. Cell necrosis due to the injection
procedure was determined using immunocytochemistry for neuronal nuclei.
Inflammatory Hyperalgesia. Persistent inflammatory pain was induced by injection of
complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl),
suspended in an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw.
Paw diameters were determined using calibrated calipers applied midpoint across the
dorsal to plantar surface of both hindpaws before and after induction of inflammation.
Inflammatory Hyperalgesia
Persistent inflammatory pain was induced by injection of complete Freund’s adjuvant
(CFA; Mycobacterium tuberculosis; Sigma; 200 µl), suspended in an oil/saline (1:1)
emulsion, into the plantar surface of the right hindpaw. Animals were under brief Isoflo
(isofluorane, USP) anesthesia during the plantar injections. Paw diameters determined
using calibrated calipers applied midpoint across the dorsal to plantar surface of both
hindpaws before baseline testing and after induction of inflammation.
Behavioral Testing
Paw withdrawal latencies to a noxious thermal stimulus were determined using the Paw
Thermal Stimulator (Univ. California San Diego) as previously described (Hargreaves et
al., 1988; Wang et al., 2006). Briefly, for this test, the rat is placed in a clear Plexiglas
box resting on an elevated glass plate maintained at 30oC. Following a one-hour
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acclimation, a radiant beam of light is positioned under the hindpaw and the time for the
rat to remove the paw from the thermal stimulus is electronically recorded as the paw
withdrawal latency (PWL). The intensity of the beam was set to produce basal PWL’s of
6-8 seconds. A maximal PWL of 20 seconds was used to prevent excessive tissue
damage due to repeated application of a noxious thermal stimulus.
Perfusion fixation
Following experimental manipulations, animals were given a lethal dose of Nembutal
(160 mg/kg; i.p.) and transcardially perfused with 200-250 ml of 0.9% sodium chloride
containing 2% sodium nitrite as a vasodilator to remove blood from the brain.
Immediately following removal of blood, 300 ml of 4% paraformaldehyde in 0.1M
phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused
through the brain as a fixative. A final rinse with 200-250 ml of the sodium
chloride/sodium nitrate solution was perfused through the brain to remove any residual
acrolein. Brains were placed in a 30% sucrose solution and stored at 4°C.
Immunohistochemistry
Perfusion fixed brains were sectioned into 25 µm coronal sections with a Leica 2000R
freezing microtome and stored free-floating in cryoprotectant-antifreeze solution
(Watson et al., 1986b) at –20oC. A 1:6 series through the rostrocaudal axis of each
brain was processed for mu opioid receptor-1 (MOR1) or neuronal nuclei (NeuN)
immunoreactivity using standard immunhistochemical techniques as previously
described (Murphy & Hoffman, 2001). Briefly, sections were rinsed extensively in
potassium phosphate-buffered saline (KPBS) immediately followed by a 20-minute
incubation in 1% sodium borohydride. The tissue was then incubated in primary
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antibody solution rabbit anti-MOR1 (donated by Robert Elde, Ph.D. at the University of
Minnesota; 1:70,000) or rabbit anti-MOR1 (Abcam, Cambridge, MA; 1,50,000; lot
317653) or mouse anti-NeuN (Chemicon, Temecula, CA; 1,50,000; lot 23112968) in
KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours
at 4°C. Both MOR1 antibodies were prepared against the synthetic peptide
(NHQLENLEAETAPLP) corresponding to amino acids 384-398 of rat MOR1 (Arvidsson
et al., 1995; Starowicz et al., 2007). After rinsing with KPBS, the tissue was incubated
for one hour in biotinylated goat anti-rabbit IgG or anti-mouse (Jackson
Immunoresearch; West Grove, PA, 1:600), rinsed with KPBS and incubated for one
hour in an avidin-biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After
rinsing in KPBS and sodium acetate (0.175 M; pH 6.5), MOR1 or NeuN
immunoreactivity was visualized as a black reaction product using nickel sulfate
intensified 3,3’-diaminobenzidine solution containing 0.08% hydrogen peroxide in
sodium acetate buffer. After 15-30 minutes, tissue was rinsed in sodium acetate buffer
followed by KPBS. Sections were then mounted out of saline onto gelatin-subbed
slides, air-dried and dehydrated in a series of graded alcohols. Tissue-mounted slides
were then cleared in xylene and glass cover-slipped using Permount.
Receptor Autoradiography
Dermorphin-saporin (n=4 males; n=4 females) and blank-saporin (n=4 males; n=4
females) treated animals were rapidly decapitated. Brains were removed rapidly, flash
frozen in 2-Methylbutane and stored at -80oC. Fresh frozen tissue was cut in a 1:4
series of 20 µm coronal sections at -20 oC with a Leica CM3050S cryostat, immediately
mounted onto glass slides and stored at -80oC. Slides were dried and fixed in 4%
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paraformaldehyde followed by rinses in 50mM Tris buffer (pH 7.4) containing 100nM
NaCl. Slides were then placed in a tracer buffer containing tritiated DAMGO (1 nM;
Amersham, Pittsburg, PA) for 60 minutes followed by a series of rinses in 50mM Tris
buffer (pH 7.4) containing MgCl2. Tissue was allowed to try and placed on
autoradiographic film for 5 weeks at which point films were developed with a FujiFilm
BAS 5000 (Valhalla, NY).
Densitometry
For immunohistochemistry data, 12-bit grayscale images were captured using a
QImaging Retiga EXi CCD camera (Surrey, BC, Canada) and IPLab Image Analysis
Software (BD Biosciences, Rockville, MD). The vlPAG was bilaterally sampled (35mm2
at 10X magnification) between Bregma -7.04 to -8.30 (Paxinos & Watson, 1997) three
times per section (6-8 sections per brain) and the average grayscale pixel value was
recorded. Measures were corrected for non-specific immunoreactivity background by
subtraction of measures taken from areas of equal size lacking specific
immunoreactivity adjacent to the vlPAG in the same section. For autoradiography data,
color images were captured and the brightness/contrast was adjusted using Fujifilm
Multigauge software (Vallhala, NY). The injection site area in the vlPAG (Bregma -7.04
to -8.30) was sampled three times per section (6-8 sections per brain), averaged and
the photo-stimulated luminescence per mm2 (PSL/mm2) was recorded. Measures were
corrected for non-specific binding by subtraction of measures taken from a same
section area adjacent to the vlPAG of equal size.
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Statistical Analysis
For behavioral data analysis, data are expressed as either raw PWL's or percent
maximal possible effect (%MPE), defined as [(PWL – CFA baseline)/(Maximal PWL –
CFA baseline)]*100 (Jensen & Yaksh, 1986). PWL data were analyzed for significant
main effects of sex and estrous cycle using ANOVA. Percentile data was transformed
into standard scores. Unpaired t-tests were used to determine significant differences in
baseline data. As no significant differences in %MPE were noted for the 30, 45 and 60
minute time points, these values were averaged for derivation of ED50, defined as the
dose of morphine that produced 50% of the maximum possible increase in PWL, with
the Prism software program and analyzed for significant reductions in values ANOVA.
P<.05 was considered statistically significant. Fisher’s post hoc tests were used to
determine specific group differences when a main effect or interaction was observed.
Specific Experiments
Experiment 1. Do sex or estrous cycle influence MOR expression in the vlPAG?
Male and female rats with an established four-day estrous cycle were perfused
transcardially with fixative on the morning a specific stage of estrous (diestrus 1, n=12;
diestrus 2, n=12; proestrus, n=12; estrus, n=12). Males (n=12) and ovariectomized
females (n=12) were sacrificed at the same time. Tissue sections were processed
immunohistochemically for MOR1 immunoreactivity (Dr. Elde’s antibody; (Arvidsson et
al., 1995; Kalyuzhny et al., 1996; Kalyuzhny & Wessendorf, 1997; 1998; Wang &
Wessendorf, 1999; Kalyuzhny et al., 2000; Wang & Wessendorf, 2002) and
densitometry values were recorded across vlPAG.
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Experiment 2. Do sex and estrous-induced changes in PAG MOR expression
influence the antihyperalgesic effects of morphine administered into the vlPAG?
Intact male and cycling female rats were implanted with cannulae directed at the
ventrolateral PAG. One week later, baseline PWLs and paw diameters were determined
followed by induction of CFA-induced inflammation. Twenty-four hours later, PWL and
paw diameters were re-determined to ensure the presence of hyperalgesia. Saline or
morphine sulfate prepared fresh on the day of experiment (obtained from the National
Institute on Drug Abuse, Rockville, MD) was injected into the PAG using a syringe pump
attached to a 33-gauge injector (7 mm; Plastics One, Roanoke, VA). Separate groups of
animals received morphine (1.75, 2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 18.0 µg) or saline in a
total volume of 0.5 µl over 60 seconds. PWLs for the inflamed paw were determined at
15, 30, 45, 60, 90 and 120 min post injection to assess morphine antihyperalgesia. At
the end of the experiment, Chicago Sky Blue dye (Sigma; St. Louis, MO) was injected
through the guide cannulae for injection site verification. Analysis was limited to those
animals with injections into the caudal vlPAG (Bregma -7.04 to -8.30).
Experiment 3. Do lesions of MOR-expressing neurons in the vlPAG attenuate the
antihyperalgesic effects of morphine? Following determination of baseline PWLs,
animals were administered either DermSAP or BlankSAP bilaterally into the vlPAG.
Twenty-eight days later, PWLs were determined (baseline pre-inflamed PWL). CFA was
then injected intraplantar to induce persistent inflammatory pain. Twenty-four hours
later, PWLs’ were determined to ensure that DermSAP had no effect on baseline
hyperalgesia. Animals then received cumulative doses of morphine every 20 minutes
(1.8, 3.2, 5.6, 8.0, 10.0,18.0 mg/kg; (Loyd et al., 2008); PWLs were determined 5 min
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post-administration. At the end of the experiment, animals were perfused and lesion
sites verified immunohistochemically with antibodies directed against MOR1 and NeuN.
An additional group of animals received either DermSAP or BlankSAP were decapitated
28 days later and receptor autoradiography was performed to examine the effectiveness
of MOR lesioning.

6.4 RESULTS
Sex differences in mu opioid receptor expression in the ventrolateral PAG
Expression of mu opioid receptor protein in the PAG of intact male and cycling female
rats was examined immunohistochemically. Within the rostral PAG, MOR
immunoreactivity was localized primarily within the dorsomedial subdivision of the PAG
and was comparable between the sexes. Moving caudally, MOR immunoreactivity
shifted and was densely localized within the vlPAG, primarily at the level of the dorsal
raphe (Bregma -7.04 to -8.30). Overall, females had significantly less MOR
immunoreactivity in the caudal vlPAG compared to males [F(2,33)=2.064; p=.1430]
(Figure 6.1A-B). As shown in Figure 6.1C, MOR expression fluctuated across the
estrous cycle, with significantly reduced MOR immunoreactivity noted in proestrus
versus diestrus females (p=.0528) and intact males (p=.0068).
Intra-vlPAG morphine produces greater antihyperalgesia in males
We have previously reported that morphine produces a significantly greater degree of
antihyperalgesia in male versus female rats (Wang et al., 2006; Ji et al., 2007). We next
tested whether sex and estrous-induced differences in PAG MOR expression drive our
observed sex differences in morphine antihyperalgesia. Intra-PAG cannulae were
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localized within the caudal vlPAG at the level of the dorsal raphe (Bregma -7.04 to 8.30). Figure 6.2 shows a representative photomicrograph of the intra-vlPAG injection
site in a male (A) and female (B) rat. Overall, microinjection of morphine directly into the
vlPAG resulted in greater antihyperalgesia in male compared to female rats
[F(1,21)=188.78; p<.0001], with a significant dose by sex interaction [F(1,21)=21.81;
p=.0001]. In male rats, intra-vlPAG morphine resulted in a dose-dependent
antihyperalgesia with the administration of 10µg resulting in 100%MPE at 30, 45 and 60
minutes post-injection (Figure 6.3A). Remarkably, in females, administration of this dose
resulted in PWLs that were not significantly different than saline controls. As there were
no significant differences in the %MPE observed for the 30, 45 and 60-minute time
points, these data are collapsed and presented for all doses (Figure 6.3B). As noted in
Figure 6.3B, in males, intra-vlPAG morphine (1.75-10µg) resulted in a dose-dependent
antihyperalgesic response, with 10µg resulting in 100%MPE. By contrast, administration
of these doses in females did not alter PWLs significantly compared to saline. Indeed,
no significant differences in the effects of morphine versus saline were noted until the
12.5µg dose in females, and even at this dose, the %MPE was only approximately 30%.
Interestingly, increasing the dose of morphine from 15µg to 18µg did not result in any
significant increase in %MPE in females (approximately 55% to 40%). A small group of
females were administered 20µg, however this dose was lethal in most of the animals
so additional testing at this dose was terminated. Similarly, administration of the 12.5µg
and 15µg doses were lethal to all males so testing at this dose was terminated.
As there was no significant difference in the %MPE between the 12, 15 and 18µg/0.5µl
doses of morphine in females, these data were collapsed and examined for a main
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effect of estrus on morphine anithyperalgesia. There was a significant main effect of
estrous stage [F(2,17)=15.35; p=.0002]; such that proestrus (p=.0001) and estrus
(p=.0005) females had significantly lower levels of morphine antihyperalgesia (2025%MPE), while diestrus females had the greatest levels of morphine antihyperalgesia
(70%MPE; Figure 6.3C). Our observed sex differences in intra-vlPAG morphine
antihyperalgesia are not due to sex or estrous differences in baseline pain sensitivity
[F(3,60)=1.027; p=.3870] (Figure 6.4A) or in CFA-induced hyperalgesia [F(3,60)=1.244;
p=.3017 (Figure 6.4B) and there was no difference in the degree of edema produced by
intraplantar CFA [F(3,60)=1.842; p=.1492] (Figure 6.4C).
Lesions of MOR-expressing neurons in the vlPAG attenuate morphine antihyperalgesia
in males only
To test the role of vlPAG MOR in driving sex differences in morphine analgesia, we
injected DermSAP into the vlPAG to site-specifically lesion MOR-expressing neurons.
Lesions that were used for analysis were limited to localization within the vlPAG
between Bregma -7.04 to -8.30 (Figure 6.5). The effectiveness of the lesions were
confirmed in three ways: (1) a significant reduction in MOR immunoreactivity (Figure
6.6A-B), (2) a reduction in neuronal nuclei without complete cell necrosis (Figure 6.6CD), and a significant reduction in tritiated DAMGO binding (Figure 6.6E-F). DermSAP
treatment significantly reduced MOR expression [F(1,19)=8.951; p=.0075] and MOR
agonist binding [F(1,12)=115.468; p<.0001] in the vlPAG compared to BlankSAP
controls. There was no evidence of cell necrosis due to the injection procedure in any of
the animals used for analysis, similar to previous reports (Porreca et al., 2001).
Lesioning MOR-expressing neurons in the vlPAG had no effect on baseline pain
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sensitivity to either a thermal [F(1,13)=.193; p=.6677] (Figure 6.7A) or mechanical
[F(1,15)=2.833; p=.1130] (Figure 6.7B) noxious stimulus in either sex. Following twentyfour hours of CFA-induced inflammation, there was no effect of lesions on thermal
[F(1,16)=.283; p=.6018] (Figure 6.7A) or mechanical [F(1,16)=.147; p=.7064] (Figure
6.7B) hyperalgesia in either sexes.
Following twenty-four hours of CFA-induced inflammation, the antihyperalgesic effects
of morphine were assessed using a cumulative dosing paradigm. BlankSAP control
male and female rats showed normal levels of morphine antihyperalgesia to cumulative
doses of morphine (Figure 6.8), with a mean average ED50 value of 4.07mg/kg in males
versus 10.39mg/kg in females. There was a significant main effect of treatment
[F(3,130)=4.750; p<.0001], such that DermSAP treated males displayed a significant
rightward shift in ED50 from 4.07mg/kg in controls to 12.55mg/kg; no significant change
in ED50 was noted in females (10.39mg/kg to 9.21mg/kg).
Positive correlation between morphine antihyperalgesia and vlPAG MOR expression
levels in males only
DermSAP treatment resulted in a differential loss of MOR protein across the caudal
vlPAG with levels ranging from abnormally low to normal or high levels. To further
examine the effect of lesioning vlPAG MOR on morphine antihyperalgesia, DermSAP
and BlankSAP animals were pooled and grouped into the following three categories
based on the extent of lesions: (1) abnormally low level of MOR immunoreactivity
(densitometry value 49.80 to 91.82; n=3 males, n=4 females), (2) moderate reduction of
MOR immunoreactivity (93.57 to 121.78; n=3 males, n=4 females) and (3) normal or
high levels of MOR immunoreactivity (126.48 to 181.33; n=4 males, n=3 females).
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Normal density of MOR expression was over two-fold higher than that of abnormal
levels of expression (Figure 6.9A; R2=.787). In males, there was a positive correlation
between the density of vlPAG MOR-expressing neurons and the level of morphine
antihyperalgesia (Figure 6.9B). Reducing the expression of MOR in the vlPAG caused a
significant reduction in ED50 in males: ED50 3.46 in males with a high expression (group
3; CI=1.7-6.9) to ED50 11.85 (group 1; CI=7.04-13.9) in males with abnormally low levels
of expression. There was no significant difference observed in females with a low
density (ED50 9.46; CI=7.8-11.6) versus a normal ‘high’ density (ED50= 8.77; CI=7.510.3) of MOR in the vlPAG (Figure 6.9C).

6.5 DISCUSSION
Many factors limit the efficacy of opiates, including tolerance (Christie et al., 1987;
Morgan et al., 2003; Bagley et al., 2005; Lane et al., 2005; Loyd et al., 2008),
dependence (Ingram et al., 1998; Williams et al., 2001; Hack et al., 2003), negative side
effects (Cepeda & Carr, 2003; Cepeda et al., 2003; Fillingim et al., 2005; Panchal et al.,
2007) and more recently, ‘gender’ or ‘sex’ (Wang et al., 2006). It is now well known that
morphine is not as potent in females compared to males; however, the mechanism
driving this phenomenon is unknown. The present experiments tested the hypothesis
that the expression of MOR in the vlPAG is sexually dimorphic and responsible for the
observed sex difference in morphine potency. Here we report that (1) males have
significantly higher levels of MOR protein in the vlPAG compared to females; (2) intravlPAG administration of morphine produces significantly greater antihyperalgesia in
males; (3) lesions of MOR-expressing PAG neurons attenuate systemic morphine
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antihyperalgesia in males only; and (4) the degree of systemic morphine-produced
antihyperalgesia is positively correlated with the density of MOR immunoreactivity in the
vlPAG.
Sex Differences in Mu Opioid Receptor Expression in the ventrolateral PAG
In male rats, studies utilizing both autoradiography and immunohistochemistry have
previously reported that the PAG contains a high density of MOR (Mansour et al., 1986;
Mansour et al., 1987; Arvidsson et al., 1995; Kalyuzhny et al., 1996; Gutstein et al.,
1998; Commons et al., 1999; Commons et al., 2000b; Wang & Wessendorf, 2002). In
the present study, the highest density of MOR immunoreactivity was observed in the
caudal vlPAG, similar to previous reports (Kalyuzhny et al., 1996; Commons et al.,
2000b). Overall, females rats had significantly less MOR immunoreactivity in the vlPAG,
with the greatest difference observed in proestrus females with approximately one-third
less labeling compared to males. Interestingly, females in diestrus, the stage where
estrogen and progesterone are the lowest, had comparable levels of MOR
immunoreactivity compared to males. These results are consistent with a recent study
that reported two fold lower MOR protein expression in the female rat midbrain
compared to males (Kren et al., 2008). These findings may indicate that steroid
hormones play a role in MOR expression in the region of the PAG that is essential for
antinociception.
Intra-vlPAG Morphine Produces Greater Antihyperalgesia in Males Compared to
Estrous and Proestrus Females
The antinociceptive effects of morphine are mediated primarily by the MOR, which is
expressed in several supraspinal sites including the habenula, striatum, hippocampus,
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locus coeruleus, the nucleus raphe magnus and the periaqueductal gray (Arvidsson et
al., 1995). Given that (1) up to 50% of PAG-RVM projection neurons contain MOR
(Commons et al., 2000b; Wang & Wessendorf, 2002) and (2) female rats have reduced
levels of MOR in the vlPAG, we hypothesized that the PAG was sufficient for sex
differences in morphine antihyperalgesia. Microinjection of morphine directly into the
vlPAG produced a significantly greater degree of analgesia in males compared to
females at all doses tested. Indeed, intra-vlPAG morphine at 10µg resulted in
100%MPE in males; while in females this dose had no antihyperalgesic effect at all until
the highest doses tested. These results indicate that females require twice the amount
of morphine, when administered into the vlPAG, as males to produce comparable levels
of antihyperalgesia. These results are consistent with our previous studies using
systemic morphine in which female ED50 values were two fold higher in male rats (Ji et
al., 2006; Wang et al., 2006).
In the present study, we observed an effect of estrous on morphine antihyperalgesia in
females. Specifically, morphine antihyperalgesia was reduced during proestrus and
estrous, in comparison to diestrus and is consistent with previous studies examining the
influence of estrous on morphine antihyperalgesia (Kepler et al., 1989; Islam et al.,
1993; Krzanowska & Bodnar, 1999; Krzanowska et al., 2002). In particular, increased
levels of morphine antihyperalgesia are observed during diestrus when estrogen and
progesterone are lowest. In fact, morphine antihyperalgesia during diestrus was not
significantly different than males. These results parallel our finding of reduced MOR
protein levels during proestrus compared to diestrus, and provide further support for our
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finding that the amount of available MOR is positively correlated with the degree of
antihyperalgesia produced by morphine.
Between 20-50% of PAG-RVM neurons retrogradely labeled from the RVM contain
receptors for the steroid hormones estrogen and androgen (Loyd & Murphy, 2008b),
while 27-50% express MOR (Commons et al., 2000b; Wang & Wessendorf, 2002);
therefore it is likely that a proportion of PAG-RVM projection neurons express both
receptor types. There are several mechanisms whereby changes in gonadal steroid
levels could influence MOR expression and ultimately, morphine antihyperalgesia. First,
several studies have reported that increased levels of estradiol result in MOR
internalization (Eckersell et al., 1998b; Micevych et al., 2003), thereby reducing
available opioid binding sites. Secondly, studies by Kelly et al. (2003) have shown that
administration of estradiol results in the rapid uncoupling of MOR from G protein-gated
inwardly rectifying potassium channels (Kelly et al., 2003) thus resulting in a reduction in
morphine’s ability to hyperpolarize PAG-RVM neurons. Obviously, further research on
the mechanism whereby estradiol alters MOR expression is warranted.
Mu Opioid-Expressing Neurons in the Ventrolateral PAG are Necessary for Sex
Differences in Morphine Antihyperalgesia
As microinjection of morphine into the vlPAG resulted in greater antihyperalgesia in
males, we next lesioned MOR-expressing vlPAG neurons to test their necessity in
driving sex differences in morphine antihyperalgesia. Using site-specific lesioning
techniques, we found that reducing the density of MOR in the caudal vlPAG significantly
attenuated morphine antihyperalgesia to systemic morphine in male but not female rats.
The ED50 in males shifted from 4.07mg/kg in controls to 12.55mg/kg in males, while no
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shift was noted in the ED50 in females. These data provide evidence that MOR
expression in the PAG is necessary for the antihyperalgesic effects of systemic
morphine, but only in males. Interestingly, removal of MOR in the PAG of females had
no impact on morphine-induced antihyperalgesia; however, at high doses of systemic
administration, morphine still produces analgesia. This suggests that in females, the
PAG is not the primary anatomical substrate for the antihyperalgesic effects of
morphine. Both the RVM (Porreca et al., 2001; Burgess et al., 2002) and in the dorsal
horn of the spinal cord (Kline & Wiley, 2008) have been shown to also contribute to
morphine antihyperalgesia and perhaps these sites are more critical in females. In
support, we have recently reported no differences in MOR expression within the
lumbosacral spinal cord and similarly, no differences in ED50 values for morphine when
administered intrathecally (Ji et al., 2006).
Administration of DermSAP resulted in a range of MOR immunoreactivity within the
caudal vlPAG. Interestingly, we found that the density of vlPAG MOR immunoreactivity
was positively correlated with morphine antihyperalgesia in male, but not female rats.
Males with normal levels of MOR immunoreactivity in the vlPAG had significantly lower
ED50 values compared to males with two-fold less MOR immunoreactivity. These results
further indicate that MOR-expressing neurons in the PAG are essential for morphine
antihyperalgesia in male but not female rats.
Our observed sex difference in the actions of morphine is not to due sex differences in
pain sensitivity or hyperalgesia. Interestingly, removal of vlPAG MOR with DermSAP
had no effect on baseline pain sensitivity or inflammatory hyperalgesia to either a
painful thermal or mechanical stimulus, indicating that removal of vlPAG MOR does not
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affect endogenous pain modulation. Thus, while vlPAG MOR obviously contributes to
the exogenous effects of morphine, its reduction does not alter the endogenous system.
Previous studies have reported that DermSAP lesions of MOR-expressing neurons in
the RVM (Porreca et al., 2001; Burgess et al., 2002) and dorsal horn neurons (Kline &
Wiley, 2008) attenuate hyperalgesia in male rats. Together, these data indicate that the
RVM and the dorsal horn of the spinal cord, but not the PAG, are essential for driving
descending facilitation (Terayama et al., 2000; Ren & Dubner, 2002; Dubner & Ren,
2004).
Importantly, our results indicate that morphine is a remarkably ineffective opiate for the
alleviation of persistent pain in females. Sex differences in morphine potency are well
known in animal research, and have also been widely reported in humans (Kest et al.,
2000; Sarton et al., 2000; Zacny, 2001; Cepeda et al., 2002; Cepeda & Carr, 2003;
Miller & Ernst, 2004). Interestingly, sex is not the only factor that has been shown to
affect the efficacy and potency of various pharmacological agents. Indeed, recent
studies have reported an influence of age (Smith & Gray, 2001; Aubrun & Marmion,
2007; Gagliese et al., 2008) and ethnicity (Kaiko et al., 1983), and further argue for the
inclusion of a wide range of study subjects in pain management research. In addition,
despite the rapidly mounting evidence of limitations of opiates in treating persistent pain,
opioid-based drugs remain the primary pharmacological tool for pain management.
Clearly additional research with the inclusion of female subjects needs to be devoted to
determining a more potent treatment for persistent pain in women.
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6.6 CHAPTER SUMMARY
Overall, we report that there are sex differences in the expression of MOR in the vlPAG
of the rat, with males having nearly 50% higher levels of MOR immunoreactivity as
compared to proestrus females. Similarly, administration of morphine into the vlPAG
produces significantly greater antihyperalgesia in males compared to females, which
suggests that sex differences in PAG MOR may provide a primary mechanism for the
sexually dimorphic effects of morphine. Furthermore, lesioning MOR-expressing
neurons in the vlPAG attenuated morphine antihyperalgesia in males only, providing
further evidence that MOR in the vlPAG is a primary anatomical substrate for the
analgesic effects of morphine. Together, these results indicate that sex differences in
MOR in the vlPAG provide a necessary and sufficient neural mechanism for eliciting sex
differences in morphine antihyperalgesia.
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Figure 6.1. A-B. Photomicrograph depicting mu opioid receptor immunoreactivity in the
caudal ventrolateral PAG (Bregma -8.00). C. Mean densitometry value of mu opioid
receptor immunoreactivity in male (closed) and proestrus, estrus and diestrus females
(open) averaged across the caudal PAG (Bregma -7.04 to -8.30). *denotes a significant
effect.
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Figure 6.2. Microphotograph of an example of an intra-PAG cannulation site for
morphine microinjection in the caudal ventrolateral PAG (Bregma -8.00) of a
representative male (A) and female (B) rat.
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Figure 6.3. A. Percent maximal possible effect (MPE) of intra-PAG morphine
administration of 5 and 10µg/µl in males (closed symbols) and 5, 10 and 18µg/µl in
female (open symbols) rats. B. Percent maximal possible effect of intra-PAG morphine
administration averaged across the time points 30, 60 and 90 minutes in male (black
bars) and female (white bars) rats. C. Percent maximal possible effect of intra-PAG
morphine administration in proestrus, estrus and diestrus females (open bars)
compared to intact male (closed bars) rats. *denotes a significant effect.
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Figure 6.4. A. Mean paw withdrawal latency (PWL) in seconds to a thermal stimulus in
proestrus, estrus and diestrus females (open bars) compared to male (closed bars) rats.
B. Mean paw withdrawal latency in seconds to a thermal stimulus following 24 hours of
CFA-induced inflammation in proestrus, estrus and diestrus females (white bars)
compared to male (black bars) rats. C. Percent change in paw diameter following 24
hours of CFA-induced inflammation.
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Figure 6.5. Illustration depicting localization of DermSAP (closed symbols) versus
BlankSAP (open symbols) injection sites within the caudal ventrolateral PAG (Bregma 7.04 to -8.30) of male (triangle) versus female (circle) rats.
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Figure 6.6. A-B. Photomicrograph depicting mu opioid receptor density in the vlPAG
(Bregma -8.00) following BlankSAP (A) versus DermSAP (B) treatment. C-D.
Photomicrograph depicting NeuN density in the vlPAG (Bregma -8.00) following
BlankSAP (C) versus DermSAP (D) treatment. E-F. Photomicrograph depicting tritiated
DAMGO binding in the vlPAG (Bregma -8.00) following BlankSAP (E) versus DermSAP
(F) treatment.
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Figure 6.7. Paw withdrawal latencies (PWL) to a thermal (A) or mechanical (B) painful
stimulus prior to surgical manipulation (Pre-Lesion), following DermSAP or BlankSAP
treatment (Pre-Inflamed), and following 24 hours of CFA-induced hyperalgesia
(Inflamed) in male (closed bars) versus female (open bars) rats.
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Figure 6.8. Percent maximal possible effect (MPE) of cumulative doses of systemic
morphine in inflamed male (triangle) and female (circle) rats following DermSAP (closed
symbols) or BlankSAP (open symbols).
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Figure 6.9. A. Degree of positive correlation of densitometry value versus grouping of
individuals based on mu opioid receptor density in the ventrolateral PAG following
DermSAP or BlankSAP treatment. B-C. Percent maximal possible effect of cumulative
doses of systemic morphine (0, 1.8, 3.2, 5.6, 8, 10, 18mg/kg) in inflamed male (B) and
female (C) rats expressing low (1), moderate (2) and high (3) mu opioid receptor
density.
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CHAPTER SEVEN

CONCLUSIONS
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7.1 SEXUALLY DIMORPHIC ORGANIZATION OF THE DESCENDING PAIN
INHIBITORY PATHWAY
We used neuroanatomical tract tracing techniques to examine whether there were
qualitative and/or quantitative differences in the projections from the PAG to the RVM in
both males and female rats. Consistent with previous anatomical studies (Beitz, 1982c;
Beitz et al., 1983; van Bockstaele et al., 1991), we reported that the dorsomedial, lateral
and ventrolateral PAG heavily project to the RVM in both male and female rats (Loyd &
Murphy, 2006). Interestingly, while no qualitative sex differences were noted in the
overall distribution of PAG-RVM output neurons, females had significantly more PAGRVM projection neurons across the rostrocaudal axis of the PAG compared to males
(Loyd et al., 2007; Loyd et al., 2008; Figure 7.1a-c). The average number of
retrogradely labeled cells across the rostrocaudal extent of the PAG was greater by a
third in female compared to male rats (Figure 7.2a). The most prominent sex difference
in retrograde labeling was observed within the lateral and ventrolateral regions of the
PAG, an area known to contain a dense distribution of mu opioid receptors (Kalyuzhny
et al., 1996; Wang & Wessendorf, 2002).

7.2 SEXUALLY DIMORPHIC PHYSIOLOGY OF THE DESCENDING PAIN
INHIBITORY PATHWAY
Sexually Dimorphic Response of the PAG-RVM Pathway to Inflammatory Pain
Inflammatory pain results in the activation of descending modulatory circuits (Morgan et
al., 1991; Williams et al., 1995) and contributes to both hyperalgesia and antinociception
(Guan et al., 2002; Miki et al., 2002; Ren & Dubner, 2002; Guan et al., 2003). We found
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that the persistent inflammatory pain induced by injection of CFA into the hindpaw
caused extensive activation of PAG neurons as measured by Fos labeling. This
activation was comparable in males and female rats (Loyd & Murphy, 2006). Although
females have almost twice the number of PAG-RVM output neurons in comparison to
males, very few of these cells in female rats expressed inflammation-induced Fos,
suggesting that this circuit is preferentially activated in males (Figure 7.2b). Indeed we
found that, overall, persistent inflammatory pain activated approximately 43% of PAGRVM neurons in the dorsomedial, lateral and ventrolateral PAG of males, but only half
as many PAG-RVM output neurons were activated by inflammatory pain in females.
Together, these data suggest that this descending modulatory circuit is not being
engaged to the same degree by persistent inflammatory pain in males and females.
Given that activation of the PAG and its descending outputs to the RVM results primarily
in the inhibition of dorsal horn neuronal responses to acute noxious stimuli (Carstens et
al., 1979; Gray & Dostrovsky, 1983; Aimone et al., 1987; Jones & Gebhart, 1988;
Waters & Lumb, 1997; Budai & Fields, 1998), reports of sex differences in the activation
of the PAG-RVM pathway may account for reported sex differences in responses to
acute noxious stimuli (Berkley, 1997; Fillingim, 2000; Fillingim & Ness, 2000; Barrett et
al., 2002).
Our findings that (1) persistent pain results in comparable activation of the PAG in both
sexes (Loyd & Murphy, 2006) and, (2) there are no sex differences in either baseline
nociceptive threshold or inflammatory pain induced hyperalgesia (Wang et al., 2006)
suggests the possibility that females utilize a distinct pathway other than the PAG-RVM
for endogenous pain modulation. We have recently begun exploring this possibility
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using combinatorial anterograde and retrograde tract-tracing in combination with
persistent pain-induced Fos labeling. The results of these studies suggest that there are
indeed sex differences in both the efferent and afferent projections of the PAG.
Specifically, the amygdala, ventromedial hypothalamus and periventricular nucleus
project more heavily to the PAG in females than males. In contrast, the medial preoptic
area, parabrachial nucleus, and locus coeruleus project more heavily to the PAG in
males than females (Loyd & Murphy, 2007b). In addition, our data indicate that the
projections to the parabrachial nucleus, locus coerulus, and the A5/A7 noraderanergic
cell group appear to be greater in males (Loyd and Murphy, unpublished observations).
Obviously, further research on the anatomy and physiology of pain modulatory circuits
in females is warranted.
Sex Differences in the Activation of the Descending Inhibitory Pathway by Morphine
Until recently, all studies examining the mechanisms of morphine action in the PAG
were conducted exclusively in males; therefore it was unknown whether morphine
administration has the same physiological effect on PAG neurons in females.
Electrophysiological studies of PAG neurons are limited because they examine the
response of a single neuron (Basbaum & Fields, 1979; Behbehani & Fields, 1979; Shah
& Dostrovsky, 1980; Behbehani, 1981; Behbehani et al., 1981; Behbehani, 1982;
Chieng & Christie, 1994b; a; Osborne et al., 1996b; Vaughan & Christie, 1997; Vaughan
et al., 1997) whereas we have shown that an important difference between males and
females is the number of neurons projecting from the PAG to the RVM (Loyd & Murphy,
2006). Moreover, electrophysiological studies have focused on the activity of PAG
neurons from males exclusively. We have addressed this problem by using tract-tracing
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techniques and Fos labeling to measure the activity of populations of PAG-RVM
neurons in the PAG of males and females. Systemic morphine administration
attenuates the persistent pain induced Fos expression within the PAG of male but not
female rats (Loyd & Murphy, 2006). This selective inhibition of Fos is consistent with our
data showing that the ED50 for systemic morphine is approximately two times higher in
females compared to males in a model of persistent inflammatory pain (Wang et al.,
2006).
In addition to the inhibition of PAG activation caused by persistent pain, morphine
activates a subset of PAG neurons that produce antinociception. Morphine activates
these PAG neurons by inhibiting tonically active GABAergic neurons (Vaughan et al.,
1997). We found that morphine administration induced an approximately two-fold
greater activation of PAG neurons compared to saline administration (Loyd et al., 2007).
Interestingly, no sex difference was observed in the activation of PAG neurons by
morphine (Figure 7.3a-c, black circles), suggesting that in the absence of pain,
morphine is equipotent in its ability to depolarize PAG neurons. However, when the
analysis was limited to PAG neurons projecting to the RVM, the number of neurons
activated by morphine was consistently and significantly higher in males compared to
females (Figure 7.3a-c, red stars) (Loyd et al., 2007). Indeed, approximately half of
PAG-RVM neurons in males were activated by morphine, whereas only 20% were
activated in females (Figure 7.2c). Together, these results suggest that morphine results
primarily in the net excitation of PAG-RVM neurons, most likely through removal of tonic
GABA inhibition (Moreau & Fields, 1986; Behbehani et al., 1990b; Vaughan & Christie,
1997; Commons et al., 2000b). The finding that very few PAG-RVM neurons were
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activated by morphine in females suggests that morphine may be engaging alternative
pathways that do not involve the RVM, thereby limiting the effectiveness of morphine as
a pain modulator.
Given that more PAG neurons project to the RVM in female compared to male rats, it is
possible that pain modulation in females is less dependent on opioids. If this is the case,
then direct activation of PAG output neurons should produce greater antinociception in
females, not males. Microinjection of the GABA antagonist bicuculline into the PAG
produces antinociception (Moreau & Fields, 1986; Morgan et al., 2003) by disinhibiting
output neurons. Surprisingly, even though females have more output neurons, the
antinociceptive effect of microinjecting bicuculline into the PAG is greater in males
(Michael M. Morgan personal communication).
Sex Differences in the Development of Tolerance to Repeated Morphine Administration
Repeated or continuous administration of morphine into the ventrolateral PAG of male
rats has been shown to result in the development of tolerance (Jacquet & Lajtha, 1976;
Siuciak & Advokat, 1987; Tortorici et al., 1999; Tortorici & Morgan, 2002; Lane et al.,
2005; Morgan et al., 2006). In addition, blocking opioid binding sites in the ventrolateral
PAG attenuates the development of tolerance to systemically administered morphine
(Lane et al., 2005). Tolerance appears to be mediated by a reduction in mu opioid
receptor signaling efficacy in PAG neurons (Bagley et al., 2005), an effect that is
reversed when mu opioid receptor coupling is enhanced via upregulated adenylate
cyclase activity (Hack et al., 2003). If the PAG-RVM pathway is essential for the
development of tolerance, then activation of the PAG-RVM pathway by morphine should
decline as tolerance develops, and changes in the activation of this pathway would
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correlate with sex differences in the development of tolerance to morphine. These
hypotheses were tested in male and female rats using behavioral testing (hot plate) and
immunohistochemistry to map the activation of the PAG-RVM pathway following
repeated morphine administration.
Morphine was administered once or twice a day for three days in rats that received
retrograde tracer injections into the RVM to examine potential changes in the activation
of PAG-RVM neurons during the development of tolerance. Repeated administration of
systemic morphine induced tolerance in males to a significantly greater extent than in
females (Loyd et al., 2008), consistent with previous research (Barrett et al., 2001;
Bernal et al., 2007). Indeed, the half maximal antinociceptive effect of a single injection
of morphine following repeated administration of morphine was two times greater for
female compared to male rats (Cicero et al., 1997; Cook & Nickerson, 2005; Ji et al.,
2006; Wang et al., 2006). In parallel, the activation of PAG-RVM neurons was
significantly attenuated following repeated morphine administration in males but not
females (Loyd et al., 2008). While there was no sex difference in the activation of the
PAG following three doses or six doses of morphine over three days (Figure 7.3d-f,
black circles), the activation of the PAG-RVM projection neurons steadily declined in
males only (Figure 7.3g-i, red stars). Activation of the PAG-RVM pathway by morphine
in female rats was minimal, and therefore did not decline significantly following repeated
administration of morphine (Figure 7.4). Together, these data provide further support for
a central role of the PAG in the development of tolerance to repeated administration of
morphine.
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7.3 GONADAL STEROID RECEPTOR EXPRESSION IN THE DESCENDING
INHIBITORY PATHWAY
The anatomical substrate(s) whereby gonadal steroids influence pain and analgesia are
unknown. Both androgen (AR) and estrogen receptors (ERα) have been localized in the
PAG in the male rat (Murphy & Hoffman, 1999; Murphy & Hoffman, 2001). Although it is
not known if these receptors are present in the female rat, they have been localized in
other species including the female cat (VanderHorst et al., 1998), golden hamster
(Boers et al., 1999), guinea pig (Turcotte & Blaustein, 1993) and the rhesus monkey
(Vanderhorst et al., 2002; VanderHorst et al., 2004). However, the anatomical
distribution of both receptor types in the PAG neurons projecting to the RVM was not
reported.
We have combined neuroanatomical tract-tracing techniques and steroid receptor
immunohistochemistry to characterized the expression of AR and ERα in the PAG-RVM
pathway of male and female rats (Loyd & Murphy, 2008a). In these studies, we found
that males had a significantly greater number of AR immunoreactive neurons localized
within the dorsomedial, lateral and ventrolateral PAG compared to females.
Interestingly, both the qualitative and quantitative expression of ERα in the PAG was
comparable between the sexes (Figure 7.1d-f). Both receptor types were preferentially
localized within the dorsomedial, lateral and ventrolateral subdivisions of the PAG and
increased in density along the rostrocaudal axis of the PAG with the highest expression
localized within the caudal PAG (Figure 7.1g-i). In addition, 30-37% of PAG-RVM output
neurons expressed AR or ERα (Figure 7.2d) with the highest density of co-labeling in
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the lateral/ventrolateral region of PAG. ERa and AR colocalization in PAG neurons
projecting to the RVM was comparable between the sexes (Loyd & Murphy, 2008a).
The high density of steroid receptors localized on PAG-RVM output neurons may
provide the biological basis for the observed sex differences in morphine analgesia.
Although there was no sex difference in the distribution of gonadal steroid receptors in
the PAG, only 27-50% of PAG-RVM neurons contain mu opioid receptor (MOR) (Wang
& Wessendorf, 2002). Given that morphine activates more of these neurons in male
compared to female rats, the interaction between morphine and sex hormones is likely
greater in the PAG of male compared to female rats.
There are several mechanisms whereby gonadal steroids may modulate opioidsensitive PAG-RVM output neurons, thereby resulting in a dimorphic response to
morphine. First, estradiol has been shown to uncouple the mu opioid receptor from G
protein-gated inwardly rectifying potassium channels (Kelly et al., 2003) resulting in an
attenuation of morphine-induced hyperpolarization. Second, estradiol has also been
shown to induce MOR internalization (Eckersell et al., 1998b), thereby reducing
available opioid binding sites on the cell membrane. Interestingly, ERα is required for
estradiol-induced MOR internalization (Micevych et al., 2003) supporting the hypothesis
that colocalization of MOR and ERα in the PAG-RVM output neurons provides a unique
mechanism through which estrogens may differentially affect morphine potency in male
and female rats.
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7.4 MU OPIOID RECEPTORS IN THE VENTROLATERAL PAG ARE ESSENTIAL
FOR SEX DIFFERENCES IN MORPHINE ANALGESIA
It is now well known that sex-based differences in opiate sensitivity are not due to the
pharmacokinetics of morphine (Cicero et al., 1996b; Craft et al., 1996; Cicero et al.,
1997; Sarton et al., 2000). Rather, sex related differences in morphine analgesia are
likely due to dissimilarities in opiate receptor density, binding and localization, as well as
sexually dimorphic opiate-responsive neural circuits. The vlPAG contains a high density
of MOR (Mansour et al., 1986; Mansour et al., 1987; Kalyuzhny et al., 1996; Gutstein et
al., 1998; Commons et al., 1999; Commons et al., 2000b; Wang & Wessendorf, 2002)
with 27-50% of PAG neurons projecting to the RVM expressing MOR (Commons et al.,
2000b; Wang & Wessendorf, 2002); these studies were conducted in males only. One
mechanism that may contribute to sex differences in morphine potency is a sexual
dimorphic MOR expression in the vlPAG, which may also depend on stage of estrous.
Indeed, vlPAG MOR expression was sexually dimorphic with proestrous females having
significantly lower levels of PAG vlMOR compared to intact male rats (Figure 7.5A). This
sex difference appears to be sufficient for sex differences in morphine potency, as
delivering morphine directly into the vlPAG produced greater morphine antihyperalgesia
in males (Figure 7.5B). Importantly, vlPAG MOR receptor expression was necessary for
sex differences in morphine potency, as removal of vlPAG MOR attenuates
antihyperalgesia in males only (Figure 7.5C) in a density-dependent fashion
(Figure7.5D).
Together, these data indicate that the MOR in vlPAG is sexually dimorphic so that
administration of morphine directly into the vlPAG results in sex difference in morphine
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antihyperalgesia, similar to our results with systemic morphine administration. These
MOR-expressing neurons in the PAG are necessary for sex differences in morphine
analgesia, and are essential for morphine analgesia in males, but not female rats.
Overall, while females have more PAG-RVM projection neurons compared to males,
these neurons are not engaged by morphine to produce an analgesic effect. It appears
that MOR protein is expressed in lower amounts in females and/or MOR receptors are
downregulated or uncoupled by estradiol as evidenced by a reduction in MOR in the
vlPAG during proestrus and a high expression of steroid receptors in the PAG-RVM
pathway. Alternatively, females may be utilizing a separate, unrecognized endogenous
system for the descending inhibition of pain at which exogenous opiates are not acting
as females and male have comparable pain thresholds before and following the
induction of inflammation.

7.5 FINAL REMARKS
Research spanning four decades has shown that the PAG, and its descending
projections to the RVM and dorsal horn of the spinal cord, constitute an essential neural
circuit for opioid-based analgesia. During the last half of that period, numerous rodent
and human studies have established sex differences in the analgesic effects of
morphine; however, the neural mechanisms underlying the sexually dimorphic actions
of morphine remain poorly understood. It is now clear that the anatomical and
physiological characteristics of the PAG and its descending projections to the RVM are
sexually dimorphic, with clear biological consequences in terms of morphine action
(Figure 7.6). Our studies, as well as those of others, have clearly shown that morphine
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is not the drug of choice for persistent pain modulation in females. Clearly, future
research efforts need to be devoted toward the identification of effective pain
therapeutics in women.
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Figure 7.1. (A-C) Distribution of cells retrogradely labeled from the rostral ventromedial
medulla in males (left) and females (right) at three representative rostrocaudal levels of
the periaqueductal gray. Each black circle represents one FG+ cell. (D-F) Distribution of
cells retrogradely labeled from the rostral ventromedial medulla that were
immunoreactive for AR (green circles) or ERα (purple circles). (G-I) Distribution of cells
retrogradely labeled from the rostral ventromedial medulla that were immunoreactive for
AR (green stars) or ERα (purple stars).
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Figure 7.2. A. Average of the mean number of periaqueductal cells retrogradely labeled
from the rostral ventromedial medulla across the rostrocaudal axis in males (left) and
females (right). B. Percentage of Fos-positive neurons that were retrogradely labeled
from the RVM in males (left) and females (right) following twenty-four hours of
inflammation. C. Average of the percentage of androgen (left) and estrogen (right)
receptor-expressing periaqueductal cells retrogradely labeled from the rostral
ventromedial medulla. D. Percentage of Fos-positive neurons that were retrogradely
labeled from the RVM in males (left) and females (right) following twenty-four hours of
inflammation and one hour of morphine (5mg/kg).
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Figure 7.3. Distribution of periaqueductal cells expressing Fos (black circles) and
periaqueductal cells retrogradely labeled from the rostral ventromedial medulla
expressing Fos (red stars) following: (A-C) one 5mg/kg dose of morphine; (D-F) one
5mg/kg dose of morphine per day for three consecutive days (G-I) or two 5mg/kg doses
of morphine per day for three consecutive days in males (left) and females (right) at
three representative rostrocaudal levels of the periaqueductal gray.
168

Figure 7.4. Percentage of Fos-positive neurons that were retrogradely labeled from the
RVM (%Fos in FG+ cells) in male (solid bars) and female (open bars) rats injected with
either morphine or saline once or twice daily for three days for the rostral (A; Bregma 6.72, -7.04, -7.74) and caudal (B; Bregma -8.00, -8.30, -8.80) PAG. A decrease in
labeling is evident with an increase in the number of morphine injections for male rats.
The # indicates a significant effect of treatment and the * indicates a significant effect of
sex. Saline: morphine naïve; 1 Dose: saline pretreatment followed by one dose of
morphine; 3 Doses: one dose of morphine per day; 6 Doses: two doses of morphine per
day.
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Figure 7.5. A. Mean densitometry values of mu opioid receptor in the caudal
ventrolateral PAG. * denotes significant difference of main effect. B. %MPE averaged
over time points 30, 60 and 90 minutes following intra-PAG morphine in males (black)
compared to females (white). C. %MPE following cumulative doses of morphine in
DermSAP (closed) and BlankSAP (open) treated male (triangle) and female (circle) rats.
D. %MPE following cumulative doses of morphine in male rats only grouped according
to density of mu opioid receptor.
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Figure 7.6. Proposed model of factors contributing to sex differences in morphine
potency. Sex differences in the PAG-RVM projections, mu opioid receptors, and
gonadal steroid receptors in the PAG (panel 1) are involved modulating the activation of
the PAG-RVM circuit (panel 2) to a differential degree in males and females to produce
sex differences in morphine potency (panel 3).
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